1
|
Bomatter P, Paillard J, Garces P, Hipp J, Engemann DA. Machine learning of brain-specific biomarkers from EEG. EBioMedicine 2024; 106:105259. [PMID: 39106531 DOI: 10.1016/j.ebiom.2024.105259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Revised: 07/05/2024] [Accepted: 07/11/2024] [Indexed: 08/09/2024] Open
Abstract
BACKGROUND Electroencephalography (EEG) has a long history as a clinical tool to study brain function, and its potential to derive biomarkers for various applications is far from exhausted. Machine learning (ML) can guide future innovation by harnessing the wealth of complex EEG signals to isolate relevant brain activity. Yet, ML studies in EEG tend to ignore physiological artefacts, which may cause problems for deriving biomarkers specific to the central nervous system (CNS). METHODS We present a framework for conceptualising machine learning from CNS versus peripheral signals measured with EEG. A signal representation based on Morlet wavelets allowed us to define traditional brain activity features (e.g. log power) and alternative inputs used by state-of-the-art ML approaches based on covariance matrices. Using more than 2600 EEG recordings from large public databases (TUAB, TDBRAIN), we studied the impact of peripheral signals and artefact removal techniques on ML models in age and sex prediction analyses. FINDINGS Across benchmarks, basic artefact rejection improved model performance, whereas further removal of peripheral signals using ICA decreased performance. Our analyses revealed that peripheral signals enable age and sex prediction. However, they explained only a fraction of the performance provided by brain signals. INTERPRETATION We show that brain signals and body signals, both present in the EEG, allow for prediction of personal characteristics. While these results may depend on specific applications, our work suggests that great care is needed to separate these signals when the goal is to develop CNS-specific biomarkers using ML. FUNDING All authors have been working for F. Hoffmann-La Roche Ltd.
Collapse
Affiliation(s)
- Philipp Bomatter
- Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Joseph Paillard
- Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Pilar Garces
- Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Jörg Hipp
- Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Denis-Alexander Engemann
- Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
| |
Collapse
|
2
|
Hernández-Sánchez LY, González-Trujano ME, Moreno DA, Martínez-Vargas D, Vibrans H, Hernandez-Leon A, Dorazco-González A, Pellicer F, Soto-Hernández M. Antinociceptive effects of Raphanus sativus sprouts involve the opioid and 5-HT 1A serotonin receptors, cAMP/cGMP pathways, and the central activity of sulforaphane. Food Funct 2024; 15:4773-4784. [PMID: 38469873 DOI: 10.1039/d3fo05229j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/13/2024]
Abstract
Raphanus sativus L. cv. Sango, commonly known as red radish, is widely consumed around the world as a vegetable, but its benefit in pain relief is not sufficiently investigated. This study aimed to evaluate the antinociceptive effects of R. sativus and a possible mechanism of action. An aqueous extract of R. sativus sprouts (AERSS) was investigated by parenteral (10, 30, and 100 mg kg-1, i.p.) and enteral (500 mg kg-1, p.o.) administration in the neurogenic and inflammatory phases of the formalin test, where gastric damage was also evaluated as a possible adverse effect. Ketorolac (5 mg kg-1, i.p.) was used as the reference drug. Endogenous opioid and 5-HT1A serotonin receptors, as well as the cAMP/NO-cGMP pathways, were explored in the study of a possible mechanism of action by using their corresponding antagonists: naloxone, 1 mg kg-1, i.p., WAY100635, 1 mg kg-1, i.p., and enzymatic activators or inhibitors, respectively. Sulforaphane (SFN), a known bioactive metabolite, was analyzed using electroencephalography (EEG) to evidence its central involvement. A significant and dose-dependent antinociceptive activity was observed with the AERSS resembling the antinociceptive effect of the reference drug, with an equivalent significant response with a dose of 500 mg kg-1, p.o. without causing gastric damage. The participation of the endogenous opioid and 5-HT1A serotonin receptors at central and peripheral levels was also observed, with a differential participation of cAMP/NO-cGMP. SFN as one metabolite produced significant changes in the EEG analysis, reinforcing its effects on the CNS. Our preclinical evidence supports the benefits of consuming Raphanus sativus cv. Sango sprouts for pain relief.
Collapse
Affiliation(s)
- Laura Yunuen Hernández-Sánchez
- Laboratorio de Neurofarmacología de Productos Naturales. Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz. Calz, México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, 14370, Ciudad de México, Mexico.
- Posgrado en Botánica, Colegio de Postgraduados Campus Montecillo. Carretera México-Texcoco Km. 36.5, Montecillo, Texcoco 56230, Estado de México, Mexico.
| | - María Eva González-Trujano
- Laboratorio de Neurofarmacología de Productos Naturales. Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz. Calz, México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, 14370, Ciudad de México, Mexico.
| | - Diego A Moreno
- Laboratorio de Fitoquímica y Alimentos Saludables (LabFAS), Grupo Calidad, Bioactividad y Seguridad, Departamento de Ciencia y Tecnología de Alimentos, CEBAS-CSIC, Campus de Espinardo 25, 30100 Murcia, Spain
| | - David Martínez-Vargas
- Laboratorio de Neurofisiología del Control y la Regulación. Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz. Calz, México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, 14370, Ciudad de México, Mexico
| | - Heike Vibrans
- Posgrado en Botánica, Colegio de Postgraduados Campus Montecillo. Carretera México-Texcoco Km. 36.5, Montecillo, Texcoco 56230, Estado de México, Mexico.
| | - Alberto Hernandez-Leon
- Laboratorio de Neurofarmacología de Productos Naturales. Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz. Calz, México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, 14370, Ciudad de México, Mexico.
| | - Alejandro Dorazco-González
- Departamento de Química Inorgánica, Instituto de Química. Circuito exterior s/n, Ciudad Universitaria, Coyoacán, 04510, Ciudad de México, Mexico
| | - Francisco Pellicer
- Laboratorio de Neurofarmacología de Productos Naturales. Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz. Calz, México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, 14370, Ciudad de México, Mexico.
| | - Marcos Soto-Hernández
- Posgrado en Botánica, Colegio de Postgraduados Campus Montecillo. Carretera México-Texcoco Km. 36.5, Montecillo, Texcoco 56230, Estado de México, Mexico.
| |
Collapse
|
3
|
Holter KM, Lekander AD, Pierce BE, Sands LP, Gould RW. Use of Quantitative Electroencephalography to Inform Age- and Sex-Related Differences in NMDA Receptor Function Following MK-801 Administration. Pharmaceuticals (Basel) 2024; 17:237. [PMID: 38399452 PMCID: PMC10892193 DOI: 10.3390/ph17020237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Revised: 02/05/2024] [Accepted: 02/07/2024] [Indexed: 02/25/2024] Open
Abstract
Sex- and age-related differences in symptom prevalence and severity have been widely reported in patients with schizophrenia, yet the underlying mechanisms contributing to these differences are not well understood. N-methyl-D-aspartate (NMDA) receptor hypofunction contributes to schizophrenia pathology, and preclinical models often use NMDA receptor antagonists, including MK-801, to model all symptom clusters. Quantitative electroencephalography (qEEG) represents a translational approach to measure neuronal activity, identify targetable biomarkers in neuropsychiatric disorders and evaluate possible treatments. Abnormalities in gamma power have been reported in patients with schizophrenia and correspond to psychosis and cognitive impairment. Further, as gamma power reflects cortical glutamate and GABA signaling, it is highly sensitive to changes in NMDA receptor function, and NMDA receptor antagonists aberrantly increase gamma power in rodents and humans. To evaluate the role of sex and age on NMDA receptor function, MK-801 (0.03-0.3 mg/kg, SC) was administered to 3- and 9-month-old male and female Sprague-Dawley rats that were implanted with wireless EEG transmitters to measure cortical brain function. MK-801-induced elevations in gamma power were observed in 3-month-old male and female and 9-month-old male rats. In contrast, 9-month-old female rats demonstrated blunted maximal elevations across a wide dose range. Importantly, MK-801-induced hyperlocomotor effects, a common behavioral screen used to examine antipsychotic-like activity, were similar across all groups. Overall, sex-by-age-related differences in gamma power support using qEEG as a translational tool to evaluate pathological progression and predict treatment response across a heterogeneous population.
Collapse
Affiliation(s)
| | | | | | | | - Robert W. Gould
- Department of Translational Neuroscience, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA; (K.M.H.)
| |
Collapse
|
4
|
Withey SL, Pizzagalli DA, Bergman J. Translational In Vivo Assays in Behavioral Biology. Annu Rev Pharmacol Toxicol 2024; 64:435-453. [PMID: 37708432 DOI: 10.1146/annurev-pharmtox-051921-093711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/16/2023]
Abstract
The failure of preclinical research to advance successful candidate medications in psychiatry has created a paradigmatic crisis in psychiatry. The Research Domain Criteria (RDoC) initiative was designed to remedy this situation with a neuroscience-based approach that employs multimodal and cross-species in vivo methodology to increase the probability of translational findings and, consequently, drug discovery. The present review underscores the feasibility of this methodological approach by briefly reviewing, first, the use of multidimensional and cross-species methodologies in traditional behavioral pharmacology and, subsequently, the utility of this approach in contemporary neuroimaging and electrophysiology research-with a focus on the value of functionally homologous studies in nonhuman and human subjects. The final section provides a brief review of the RDoC, with a focus on the potential strengths and weaknesses of its domain-based underpinnings. Optimistically, this mechanistic and multidimensional approach in neuropsychiatric research will lead to novel therapeutics for the management of neuropsychiatric disorders.
Collapse
Affiliation(s)
- Sarah L Withey
- Preclinical Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts, USA;
- Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
- McLean Imaging Center, McLean Hospital, Belmont, Massachusetts, USA
| | - Diego A Pizzagalli
- Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
- McLean Imaging Center, McLean Hospital, Belmont, Massachusetts, USA
- Center for Depression, Anxiety and Stress Research, McLean Hospital, Belmont, Massachusetts, USA
| | - Jack Bergman
- Preclinical Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts, USA;
- Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
5
|
Reeves-Darby JA, Berro LF, Platt DM, Rüedi-Bettschen D, Shaffery JP, Rowlett JK. Pharmaco-EEG analysis of ligands varying in selectivity for α1 subunit-containing GABA A receptors during the active phase in rats. Psychopharmacology (Berl) 2023; 240:2561-2571. [PMID: 37608193 PMCID: PMC10795493 DOI: 10.1007/s00213-023-06450-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Accepted: 08/07/2023] [Indexed: 08/24/2023]
Abstract
RATIONALE Benzodiazepines are known to evoke changes in cortical electrophysiological activity that can be correlated with action at distinct γ-aminobutyric acid type A (GABAA) receptor subtypes. OBJECTIVES We used electroencephalography (EEG) paired with electromyography (EMG) to evaluate the role of α1 subunit-containing GABAA receptors (α1GABAARs) in benzodiazepine-induced sedation and changes in EEG band frequencies during the active phase of the light/dark cycle. METHODS Male Sprague-Dawley rats (N = 4/drug) were surgically instrumented with EEG/EMG electrodes. The rats were injected i.p. with zolpidem, an α1GABAAR-preferring compound, or L-838,417, which has selective efficacy for α2/3/5 subunit-containing GABAARs (i.e., α1GABAAR-sparing compound), in comparison with the non-selective benzodiazepine, triazolam. RESULTS All ligands evaluated induced changes in sleep-wake states during the active phase consistent with an increase in slow-wave sleep (SWS). The degree of SWS increase appeared to be related to the magnitude of delta power band changes induced by the ligands, with the strongest effects engendered by the α1GABAAR-preferring drug zolpidem and the weakest effects by the α1GABAAR-sparing compound, L-838,417. Consistent with other research, a selective increase in beta band power was observed with L-838,417, which may be associated with α2GABAAR-mediated anxiolysis. CONCLUSIONS Overall, these findings support the establishment of pharmaco-EEG "signatures" for identifying subtype-selective GABAA modulators in vivo.
Collapse
Affiliation(s)
- Jaren A Reeves-Darby
- Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
- Graduate Program in Neuroscience, University of Mississippi Medical Center, Jackson, MS, 39216, USA
| | - Lais F Berro
- Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
- Graduate Program in Neuroscience, University of Mississippi Medical Center, Jackson, MS, 39216, USA
- Center for Innovation and Discovery in Addictions, University of Mississippi Medical Center, Jackson, MS, 39216, USA
| | - Donna M Platt
- Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
- Graduate Program in Neuroscience, University of Mississippi Medical Center, Jackson, MS, 39216, USA
- Center for Innovation and Discovery in Addictions, University of Mississippi Medical Center, Jackson, MS, 39216, USA
| | - Daniela Rüedi-Bettschen
- Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
- Graduate Program in Neuroscience, University of Mississippi Medical Center, Jackson, MS, 39216, USA
- Center for Innovation and Discovery in Addictions, University of Mississippi Medical Center, Jackson, MS, 39216, USA
| | - James P Shaffery
- Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA
| | - James K Rowlett
- Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA.
- Graduate Program in Neuroscience, University of Mississippi Medical Center, Jackson, MS, 39216, USA.
- Center for Innovation and Discovery in Addictions, University of Mississippi Medical Center, Jackson, MS, 39216, USA.
| |
Collapse
|
6
|
Carrle FP, Hollenbenders Y, Reichenbach A. Generation of synthetic EEG data for training algorithms supporting the diagnosis of major depressive disorder. Front Neurosci 2023; 17:1219133. [PMID: 37849893 PMCID: PMC10577178 DOI: 10.3389/fnins.2023.1219133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Accepted: 09/05/2023] [Indexed: 10/19/2023] Open
Abstract
Introduction Major depressive disorder (MDD) is the most common mental disorder worldwide, leading to impairment in quality and independence of life. Electroencephalography (EEG) biomarkers processed with machine learning (ML) algorithms have been explored for objective diagnoses with promising results. However, the generalizability of those models, a prerequisite for clinical application, is restricted by small datasets. One approach to train ML models with good generalizability is complementing the original with synthetic data produced by generative algorithms. Another advantage of synthetic data is the possibility of publishing the data for other researchers without risking patient data privacy. Synthetic EEG time-series have not yet been generated for two clinical populations like MDD patients and healthy controls. Methods We first reviewed 27 studies presenting EEG data augmentation with generative algorithms for classification tasks, like diagnosis, for the possibilities and shortcomings of recent methods. The subsequent empirical study generated EEG time-series based on two public datasets with 30/28 and 24/29 subjects (MDD/controls). To obtain baseline diagnostic accuracies, convolutional neural networks (CNN) were trained with time-series from each dataset. The data were synthesized with generative adversarial networks (GAN) consisting of CNNs. We evaluated the synthetic data qualitatively and quantitatively and finally used it for re-training the diagnostic model. Results The reviewed studies improved their classification accuracies by between 1 and 40% with the synthetic data. Our own diagnostic accuracy improved up to 10% for one dataset but not significantly for the other. We found a rich repertoire of generative models in the reviewed literature, solving various technical issues. A major shortcoming in the field is the lack of meaningful evaluation metrics for synthetic data. The few studies analyzing the data in the frequency domain, including our own, show that only some features can be produced truthfully. Discussion The systematic review combined with our own investigation provides an overview of the available methods for generating EEG data for a classification task, their possibilities, and shortcomings. The approach is promising and the technical basis is set. For a broad application of these techniques in neuroscience research or clinical application, the methods need fine-tuning facilitated by domain expertise in (clinical) EEG research.
Collapse
Affiliation(s)
- Friedrich Philipp Carrle
- Center for Machine Learning, Heilbronn University, Heilbronn, Germany
- Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany
| | - Yasmin Hollenbenders
- Center for Machine Learning, Heilbronn University, Heilbronn, Germany
- Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany
| | - Alexandra Reichenbach
- Center for Machine Learning, Heilbronn University, Heilbronn, Germany
- Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany
| |
Collapse
|
7
|
Huang SS, Yu YH, Chen HH, Hung CC, Wang YT, Chang CH, Peng SJ, Kuo PH. Functional connectivity analysis on electroencephalography signals reveals potential biomarkers for treatment response in major depression. BMC Psychiatry 2023; 23:554. [PMID: 37528355 PMCID: PMC10394892 DOI: 10.1186/s12888-023-04958-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Accepted: 06/13/2023] [Indexed: 08/03/2023] Open
Abstract
BACKGROUND The treatment efficacy varies across individual patients with major depressive disorder (MDD). It lacks robust electroencephalography (EEG) markers for an antidepressant-responsive phenotype. METHOD This is an observational study enrolling 28 patients with MDD and 33 healthy controls (mean age of 40.7 years, and 71.4% were women). Patients underwent EEG exams at baseline (week0) and week1, while controls' EEG recordings were acquired only at week0. A resting eye-closing EEG segment was analyzed for functional connectivity (FC). Four parameters were used in FC analysis: (1) node strength (NS), (2) global efficiency (GE), (3) clustering coefficient (CC), and (4) betweenness centrality (BC). RESULTS We found that controls had higher values in delta wave in the indices of NS, GE, BC, and CC than MDD patients at baseline. After treatment with antidepressants, patients' FC indices improved significantly, including GE, mean CC, and mean NS in the delta wave. The FC in the alpha and beta bands of the responders were higher than those of the non-responders. CONCLUSIONS The FC of the MDD patients at baseline without treatment was worse than that of controls. After treatment, the FC improved and was close to the values of controls. Responders showed better FC in the high-frequency bands than non-responders, and this feature exists in both pre-treatment and post-treatment EEG.
Collapse
Affiliation(s)
- Shiau-Shian Huang
- Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
- College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
- Bali Psychiatric Center, Ministry of Health and Welfare, New Taipei, Taiwan
| | - Yu-Hsiang Yu
- College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
- Division of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan
| | - His-Han Chen
- Department of Psychiatry, Yang Ji Mental Hospital, Keelung, Taiwan
| | - Chia-Chun Hung
- Bali Psychiatric Center, Ministry of Health and Welfare, New Taipei, Taiwan
| | - Yao-Ting Wang
- Bali Psychiatric Center, Ministry of Health and Welfare, New Taipei, Taiwan
| | - Chieh Hsin Chang
- Bali Psychiatric Center, Ministry of Health and Welfare, New Taipei, Taiwan
| | - Syu-Jyun Peng
- Program in Artificial Intelligence in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
| | - Po-Hsiu Kuo
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
- Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan.
- Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
| |
Collapse
|
8
|
Onofre-Campos D, González-Trujano ME, Moreno-Pérez GF, Narváez-González F, González-Gómez JD, Villasana-Salazar B, Martínez-Vargas D. Anxiolytic-like Effects and Quantitative EEG Profile of Palmitone Induces Responses Like Buspirone Rather Than Diazepam as Clinical Drugs. Molecules 2023; 28:molecules28093680. [PMID: 37175090 PMCID: PMC10180017 DOI: 10.3390/molecules28093680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 04/06/2023] [Accepted: 04/17/2023] [Indexed: 05/15/2023] Open
Abstract
Anxiety is a mental disorder with a growing worldwide incidence due to the SARS-CoV-2 virus pandemic. Pharmacological therapy includes drugs such as benzodiazepines (BDZs) or azapirones like buspirone (BUSP) or analogs, which unfortunately produce severe adverse effects or no immediate response, respectively. Medicinal plants or their bioactive metabolites are a shared global alternative to treat anxiety. Palmitone is one active compound isolated from Annona species due to its tranquilizing activity. However, its influence on neural activity and possible mechanism of action are unknown. In this study, an electroencephalographic (EEG) spectral power analysis was used to corroborate its depressant activity in comparison with the anxiolytic-like effects of reference drugs such as diazepam (DZP, 1 mg/kg) and BUSP (4 mg/kg) or 8-OH-DPAT (1 mg/kg), alone or in the presence of the GABAA (picrotoxin, PTX, 1 mg/kg) or serotonin 5-HT1A receptor antagonists (WAY100634, WAY, 1 mg/kg). The anxiolytic-like activity was assayed using the behavioral response of mice employing open-field, hole-board, and plus-maze tests. EEG activity was registered in both the frontal and parietal cortex, performing a 10 min baseline and 30 min recording after the treatments. As a result, anxiety-like behavior was significantly decreased in mice administered with palmitone, DZP, BUSP, or 8-OH-DPAT. The effect of palmitone was equivalent to that produced by 5-HT1A receptor agonists but 50% less effective than DZP. The presence of PTX and WAY prevented the anxiolytic-like response of DZP and 8-OH-DPAT, respectively. Whereas only the antagonist of the 5-HT1A receptor (WAY) inhibited the palmitone effects. Palmitone and BUSP exhibited similar changes in the relative power bands after the spectral power analysis. This response was different to the changes induced by DZP. In conclusion, brain electrical activity was associated with the anxiolytic-like effects of palmitone implying a serotoninergic rather than a GABAergic mechanism of action.
Collapse
Affiliation(s)
- Daniela Onofre-Campos
- Laboratorio de Neurofarmacología de Productos Naturales, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calz. México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, Ciudad de México 14370, Mexico
- Biología Experimental, Universidad Autónoma Metropolitana, Ciudad de México 09340, Mexico
| | - María Eva González-Trujano
- Laboratorio de Neurofarmacología de Productos Naturales, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calz. México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, Ciudad de México 14370, Mexico
| | - Gabriel Fernando Moreno-Pérez
- Laboratorio de Neurofarmacología de Productos Naturales, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calz. México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, Ciudad de México 14370, Mexico
| | - Fernando Narváez-González
- ISSSTE Hospital Regional General Ignacio Zaragoza, Calz. Ignacio Zaragoza 1840, Juan Escutia, Iztapalapa, Ciudad de México 09100, Mexico
| | - José David González-Gómez
- Laboratorio de Neurofisiología del Control y la Regulación, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calz. México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, Ciudad de México 14370, Mexico
| | - Benjamín Villasana-Salazar
- Laboratorio de Neurofisiología del Control y la Regulación, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calz. México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, Ciudad de México 14370, Mexico
| | - David Martínez-Vargas
- Laboratorio de Neurofisiología del Control y la Regulación, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calz. México-Xochimilco 101, Col. San Lorenzo Huipulco, Tlalpan, Ciudad de México 14370, Mexico
| |
Collapse
|
9
|
Joucla C, Gabriel D, Ortega JP, Haffen E. Three simple steps to improve the interpretability of EEG-SVM studies. J Neurophysiol 2022; 128:1375-1382. [PMID: 36169205 DOI: 10.1152/jn.00221.2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Machine-learning systems that classify electroencephalography (EEG) data offer important perspectives for the diagnosis and prognosis of a wide variety of neurological and psychiatric conditions, but their clinical adoption remains low. We propose here that much of the difficulties translating EEG-machine-learning research to the clinic result from consistent inaccuracies in their technical reporting, which severely impair the interpretability of their often-high claims of performance. Taking example from a major class of machine-learning algorithms used in EEG research, the support-vector machine (SVM), we highlight three important aspects of model development (normalization, hyperparameter optimization, and cross-validation) and show that, while these three aspects can make or break the performance of the system, they are left entirely undocumented in a shockingly vast majority of the research literature. Providing a more systematic description of these aspects of model development constitute three simple steps to improve the interpretability of EEG-SVM research and, in fine, its clinical adoption.
Collapse
Affiliation(s)
- Coralie Joucla
- Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive (LINC), Université de Bourgogne Franche-Comté, Besançon, France.,FEMTO-ST Institute (CNRS/Université de Bourgogne Franche Comté), Besançon, France
| | - Damien Gabriel
- Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive (LINC), Université de Bourgogne Franche-Comté, Besançon, France.,Hôpital Universitaire CHRU, Besançon, France
| | - Juan-Pablo Ortega
- Division of Mathematical Sciences, Nanyang Technological University, Singapore
| | - Emmanuel Haffen
- Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive (LINC), Université de Bourgogne Franche-Comté, Besançon, France.,Hôpital Universitaire CHRU, Besançon, France.,Clinical Psychiatry, Hôpital Universitaire CHRU, Besançon, France
| |
Collapse
|
10
|
Predictive Power of Cognitive Biomarkers in Neurodegenerative Disease Drug Development: Utility of the P300 Event-Related Potential. Neural Plast 2022; 2022:2104880. [PMID: 36398135 PMCID: PMC9666049 DOI: 10.1155/2022/2104880] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 10/08/2022] [Indexed: 11/11/2022] Open
Abstract
Neurodegenerative diseases, such as Alzheimer's disease (AD), and their associated deterioration of cognitive function are common causes of disability. The slowly developing pathology of neurodegenerative diseases necessitates early diagnosis and monitored long-term treatment. Lack of effective therapies coupled with an improved rate of early diagnosis in our aging population have created an urgent need for the development of novel drugs, as well as the need for reliable biomarkers for treatment response. These issues are especially relevant for AD, in which the rate of clinical trial drug failures has been very high. Frequently used biomarker evaluation procedures, such as positron emission tomography or cerebrospinal fluid measurements of phospho-tau and amyloid beta, are invasive and costly, and not universally available or accessible. This review considers the functionality of the event-related potential (ERP) P300 methodology as a surrogate biomarker for predicting the procognitive potential of drugs in clinical development for neurocognitive disorders. Through the application of standardized electroencephalography (EEG) described here, ERP P300 can be reliably measured. The P300 waveform objectively measures large-scale neuronal network functioning and working memory processes. Increased ERP P300 latency has been reported throughout the literature in disorders of cognition, supporting the potential utility of ERP P300 as a biomarker in many neurological and neuropsychiatric disorders, including AD. Specifically, evidence presented here supports ERP P300 latency as a quantitative, unbiased measure for detecting changes in cognition in patients with AD dementia through the progression from mild to moderate cognitive impairment and after drug treatment.
Collapse
|
11
|
Wattanathorn J, Somboonporn W, Thukham-Mee W, Sungkamnee S. Memory-Enhancing Effect of 8-Week Consumption of the Quercetin-Enriched Culinary Herbs-Derived Functional Ingredients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Foods 2022; 11:foods11172678. [PMID: 36076862 PMCID: PMC9455773 DOI: 10.3390/foods11172678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 08/22/2022] [Accepted: 08/27/2022] [Indexed: 11/24/2022] Open
Abstract
Due to great demand for memory enhancers, the memory-enhancing effects and the possible underlying mechanisms of the functional ingredients derived from the combined extract of Polygonum odoratum and Morus alba were investigated. A total of 45 participants randomly received either a placebo or the developed herbal supplement at a dose of 50 or 1500 mg/day. The consumption was done once daily for 8 weeks. Working memory was assessed via both an event-related potential and computerized battery tests at baseline and at the end of the 8-week study period. Acetylcholinesterase (AChE) and monoamine oxidase type A and type B (MAO-A, MAO-B) levels were also measured at the end of the study. The subjects who consumed the supplement containing a developed functional ingredient at a dose of 1500 mg/day showed reduced latencies but increased amplitudes of N100 and P300. An improvement in working memory and the suppression of AChE, MAO-A, and MAO-B activities were also observed. Therefore, this study clearly demonstrates the cognitive enhancing effect of the developed herbal congee, which may be associated with the suppressions of AChE and both types of MAO.
Collapse
Affiliation(s)
- Jintanaporn Wattanathorn
- Department of Physiology, Faculty of Medicine, Research Institute of High Human Performance and Health Promotion, Khon Kaen University, Khon Kaen 40002, Thailand
- Correspondence: ; Tel.: +66-81-8721809
| | - Woraluck Somboonporn
- Department of Obstetrics and Gynecology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
| | - Wipawee Thukham-Mee
- Department of Physiology, Faculty of Medicine, Research Institute of High Human Performance and Health Promotion, Khon Kaen University, Khon Kaen 40002, Thailand
| | - Sudarat Sungkamnee
- Department of Physiology, Faculty of Medicine, Research Institute of High Human Performance and Health Promotion, Khon Kaen University, Khon Kaen 40002, Thailand
| |
Collapse
|
12
|
Buchhalter J, Neuray C, Cheng JY, D’Cruz O, Datta AN, Dlugos D, French J, Haubenberger D, Hulihan J, Klein P, Komorowski RW, Kramer L, Lothe A, Nabbout R, Perucca E, der Ark PV. EEG Parameters as Endpoints in Epilepsy Clinical Trials- An Expert Panel Opinion Paper. Epilepsy Res 2022; 187:107028. [DOI: 10.1016/j.eplepsyres.2022.107028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2022] [Revised: 08/29/2022] [Accepted: 09/26/2022] [Indexed: 11/30/2022]
|
13
|
Assecondi S, Villa-Sánchez B, Shapiro K. Event-Related Potentials as Markers of Efficacy for Combined Working Memory Training and Transcranial Direct Current Stimulation Regimens: A Proof-of-Concept Study. Front Syst Neurosci 2022; 16:837979. [PMID: 35547238 PMCID: PMC9083230 DOI: 10.3389/fnsys.2022.837979] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Accepted: 03/28/2022] [Indexed: 11/14/2022] Open
Abstract
Our brains are often under pressure to process a continuous flow of information in a short time, therefore facing a constantly increasing demand for cognitive resources. Recent studies have highlighted that a lasting improvement of cognitive functions may be achieved by exploiting plasticity, i.e., the brain’s ability to adapt to the ever-changing cognitive demands imposed by the environment. Transcranial direct current stimulation (tDCS), when combined with cognitive training, can promote plasticity, amplify training gains and their maintenance over time. The availability of low-cost wearable devices has made these approaches more feasible, albeit the effectiveness of combined training regimens is still unclear. To quantify the effectiveness of such protocols, many researchers have focused on behavioral measures such as accuracy or reaction time. These variables only return a global, non-specific picture of the underlying cognitive process. Electrophysiology instead has the finer grained resolution required to shed new light on the time course of the events underpinning processes critical to cognitive control, and if and how these processes are modulated by concurrent tDCS. To the best of our knowledge, research in this direction is still very limited. We investigate the electrophysiological correlates of combined 3-day working memory training and non-invasive brain stimulation in young adults. We focus on event-related potentials (ERPs), instead of other features such as oscillations or connectivity, because components can be measured on as little as one electrode. ERP components are, therefore, well suited for use with home devices, usually equipped with a limited number of recording channels. We consider short-, mid-, and long-latency components typically elicited by working memory tasks and assess if and how the amplitude of these components are modulated by the combined training regimen. We found no significant effects of tDCS either behaviorally or in brain activity, as measured by ERPs. We concluded that either tDCS was ineffective (because of the specific protocol or the sample under consideration, i.e., young adults) or brain-related changes, if present, were too subtle. Therefore, we suggest that other measures of brain activity may be more appropriate/sensitive to training- and/or tDCS-induced modulations, such as network connectivity, especially in young adults.
Collapse
Affiliation(s)
- Sara Assecondi
- Center for Mind/Brain Sciences, University of Trento, Rovereto, Italy
- Visual Experience Laboratory, School of Psychology, University of Birmingham, Birmingham, United Kingdom
- Center for Human Brain Health, University of Birmingham, Birmingham, United Kingdom
- *Correspondence: Sara Assecondi, ,
| | | | - Kim Shapiro
- Visual Experience Laboratory, School of Psychology, University of Birmingham, Birmingham, United Kingdom
- Center for Human Brain Health, University of Birmingham, Birmingham, United Kingdom
| |
Collapse
|
14
|
Hua X, Church K, Walker W, L'Hostis P, Viardot G, Danjou P, Hendrix S, Moebius HJ. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial. J Alzheimers Dis 2022; 86:1399-1413. [PMID: 35180125 PMCID: PMC9108585 DOI: 10.3233/jad-215511] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Background: Fosgonimeton (ATH-1017) is being developed as a first-in-class regenerative therapy for people with Alzheimer’s disease (AD) and dementia; potentially improving dementia symptoms and altering disease progression by reversing synaptic disconnection and neuronal loss. Objective: This randomized, double-blind, placebo-controlled phase I trial (NCT03298672) evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of fosgonimeton. Methods: Fosgonimeton was administered once daily via subcutaneous injection to 88 subjects. The single ascending dose study enrolled healthy young male subjects (n = 48; age, 33.4±6.3 years; dose, 2, 6, 20, 40, 60, or 90 mg); the multiple ascending dose study enrolled healthy elderly subjects (n = 29; age, 63.8±4.0 years; dose, 20, 40, 60, or 80 mg; 9-day duration); and the fixed-dose study enrolled AD subjects (n = 11; age, 69.2±7.1 years; dose, 40 mg; 9-day duration). Quantitative electroencephalogram (qEEG) and event-related potential (ERP) P300 measured neurophysiological signals following fosgonimeton treatment, supporting brain penetration and target engagement. Results: Fosgonimeton and placebo were shown to be safe and well-tolerated across all doses. Pharmacokinetic results for fosgonimeton were dose-proportional, with no sex effect or accumulation over 9 days. The main effect of fosgonimeton on qEEG was acute and sustained gamma power induction. In AD subjects, there was a significant effect toward ERP P300 latency normalization compared with placebo (p = 0.027; n = 7 at 40 mg fosgonimeton versus n = 4 placebo). Conclusion: These results support the continued development of fosgonimeton as a novel therapeutic for people with AD and dementia. The fast-onset normalization of ERP P300 latency in AD subjects suggests enhancement of synaptic function and potential procognitive effects.
Collapse
Affiliation(s)
- Xue Hua
- Athira Pharma, Inc., Bothell, WA, USA
| | | | | | - Philippe L'Hostis
- Core Lab, Drug Evaluation and Pharmacology Research, Biotrial, Rennes, France
| | - Geoffrey Viardot
- Core Lab, Drug Evaluation and Pharmacology Research, Biotrial, Rennes, France
| | - Philippe Danjou
- Phase 1 Unite, Drug Evaluation and Pharmacology Research, Biotrial, Newark, NJ, USA
| | | | | |
Collapse
|
15
|
McCarthy AP, Svensson KA, Shanks E, Brittain C, Eastwood BJ, Kielbasa W, Biglan KM, Wafford KA. The dopamine D1 receptor positive allosteric modulator mevidalen (LY3154207) enhances wakefulness in the humanized D1 mouse and in sleep deprived healthy volunteers.. J Pharmacol Exp Ther 2021; 380:143-152. [PMID: 34893551 DOI: 10.1124/jpet.121.000719] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Accepted: 12/03/2021] [Indexed: 11/22/2022] Open
Abstract
Dopamine (DA) plays a key role in several central functions including cognition, motor activity and wakefulness. While efforts to develop D1 agonists have been challenging, a positive allosteric modulator (PAM), represents an attractive approach with potential better drug-like properties. Our previous study demonstrated an acceptable safety and tolerability profile of the D1 PAM mevidalen (LY3154207) in single and multiple ascending dose studies in healthy volunteers (Wilbraham et al., 2020). Herein, we describe the effects of mevidalen on sleep and wakefulness in the humanized dopamine D1 mice (hD1) and in sleep deprived healthy volunteers. Mevidalen enhanced wakefulness (latency to fall asleep) in the hD1 mouse in a dose dependent (3-100 mg/kg, PO) fashion when measured during the light (ZT-5) and predominantly inactive phase. Mevidalen promoted wakefulness in mice following prior sleep deprivation and delayed sleep onset by 5.5 and 15.2-fold compared to vehicle treated animals, after the 20 and 60 mg/kg PO doses respectively, when compared to vehicle treated animals. In humans, mevidalen demonstrated a dose-dependent increase in latency to sleep onset as measured by the multiple sleep latency test and all doses (15, 30, 75 mg) separated from placebo at the first 2-hour post dose time point. with a circadian effect at the 6-hour post-dose time point. Sleep-wakefulness should be considered as a translational biomarker for the D1PAM mechanism. Significance Statement This is the first translational study describing the effects of a selective D1PAM on sleep wakefulness in the hD1 mouse and in sleep deprived healthy volunteers. In both the human and mouse, drug exposure was correlated to sleep latency supporting the use of sleep-wake activity as a translational central biomarker for the mechanism. Overall, the wake promoting effects of D1PAMs including mevidalen may offer therapeutic opportunities in several conditions including sleep disorders and excessive daytime sleepiness related to neurodegenerative disorders.
Collapse
Affiliation(s)
| | | | - Elaine Shanks
- Exploratory Medicine and Pharmacology, Eli Lilly and Company, United Kingdom
| | | | | | | | | | | |
Collapse
|
16
|
McWilliams EC, Barbey FM, Dyer JF, Islam MN, McGuinness B, Murphy B, Nolan H, Passmore P, Rueda-Delgado LM, Buick AR. Feasibility of Repeated Assessment of Cognitive Function in Older Adults Using a Wireless, Mobile, Dry-EEG Headset and Tablet-Based Games. Front Psychiatry 2021; 12:574482. [PMID: 34276428 PMCID: PMC8281974 DOI: 10.3389/fpsyt.2021.574482] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2020] [Accepted: 03/18/2021] [Indexed: 02/01/2023] Open
Abstract
Access to affordable, objective and scalable biomarkers of brain function is needed to transform the healthcare burden of neuropsychiatric and neurodegenerative disease. Electroencephalography (EEG) recordings, both resting and in combination with targeted cognitive tasks, have demonstrated utility in tracking disease state and therapy response in a range of conditions from schizophrenia to Alzheimer's disease. But conventional methods of recording this data involve burdensome clinic visits, and behavioural tasks that are not effective in frequent repeated use. This paper aims to evaluate the technical and human-factors feasibility of gathering large-scale EEG using novel technology in the home environment with healthy adult users. In a large field study, 89 healthy adults aged 40-79 years volunteered to use the system at home for 12 weeks, 5 times/week, for 30 min/session. A 16-channel, dry-sensor, portable wireless headset recorded EEG while users played gamified cognitive and passive tasks through a tablet application, including tests of decision making, executive function and memory. Data was uploaded to cloud servers and remotely monitored via web-based dashboards. Seventy-eight participants completed the study, and high levels of adherence were maintained throughout across all age groups, with mean compliance over the 12-week period of 82% (4.1 sessions per week). Reported ease of use was also high with mean System Usability Scale scores of 78.7. Behavioural response measures (reaction time and accuracy) and EEG components elicited by gamified stimuli (P300, ERN, Pe and changes in power spectral density) were extracted from the data collected in home, across a wide range of ages, including older adult participants. Findings replicated well-known patterns of age-related change and demonstrated the feasibility of using low-burden, large-scale, longitudinal EEG measurement in community-based cohorts. This technology enables clinically relevant data to be recorded outside the lab/clinic, from which metrics underlying cognitive ageing could be extracted, opening the door to potential new ways of developing digital cognitive biomarkers for disorders affecting the brain.
Collapse
Affiliation(s)
| | | | - John F. Dyer
- Cumulus Neuroscience Ltd, Belfast, United Kingdom
| | | | - Bernadette McGuinness
- Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom
| | - Brian Murphy
- Cumulus Neuroscience Ltd, Dublin, Ireland
- School of Electronics, Electrical Engineering and Computer Science, Queen's University Belfast, Belfast, United Kingdom
| | - Hugh Nolan
- Cumulus Neuroscience Ltd, Dublin, Ireland
| | - Peter Passmore
- Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom
| | - Laura M. Rueda-Delgado
- Cumulus Neuroscience Ltd, Dublin, Ireland
- Trinity Centre for Biomedical Engineering, Trinity College, The University of Dublin, Dublin, Ireland
| | - Alison R. Buick
- Cumulus Neuroscience Ltd, Belfast, United Kingdom
- School of Electronics, Electrical Engineering and Computer Science, Queen's University Belfast, Belfast, United Kingdom
| |
Collapse
|
17
|
Kangas BD, Iturra-Mena AM, Robble MA, Luc OT, Potter D, Nickels S, Bergman J, Carlezon WA, Pizzagalli DA. Concurrent electrophysiological recording and cognitive testing in a rodent touchscreen environment. Sci Rep 2021; 11:11665. [PMID: 34083596 PMCID: PMC8175731 DOI: 10.1038/s41598-021-91091-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Accepted: 05/18/2021] [Indexed: 02/04/2023] Open
Abstract
Challenges in therapeutics development for neuropsychiatric disorders can be attributed, in part, to a paucity of translational models capable of capturing relevant phenotypes across clinical populations and laboratory animals. Touch-sensitive procedures are increasingly used to develop innovative animal models that better align with testing conditions used in human participants. In addition, advances in electrophysiological techniques have identified neurophysiological signatures associated with characteristics of neuropsychiatric illness. The present studies integrated these methodologies by developing a rat flanker task with electrophysiological recordings based on reverse-translated protocols used in human electroencephalogram (EEG) studies of cognitive control. Various touchscreen-based stimuli were evaluated for their ability to efficiently gain stimulus control and advance to flanker test sessions. Optimized stimuli were then examined for their elicitation of prototypical visual evoked potentials (VEPs) across local field potential (LFP) wires and EEG skull screws. Of the stimuli evaluated, purple and green photographic stimuli were associated with efficient training and expected flanker interference effects. Orderly stimulus-locked outcomes were also observed in VEPs across LFP and EEG recordings. These studies along with others verify the feasibility of concurrent electrophysiological recordings and rodent touchscreen-based cognitive testing and encourage future use of this integrated approach in therapeutics development.
Collapse
Affiliation(s)
- Brian D. Kangas
- grid.38142.3c000000041936754XHarvard Medical School, McLean Hospital, 115 Mill Street, Belmont, MA 02478 USA
| | - Ann M. Iturra-Mena
- grid.38142.3c000000041936754XHarvard Medical School, McLean Hospital, 115 Mill Street, Belmont, MA 02478 USA
| | - Mykel A. Robble
- grid.38142.3c000000041936754XHarvard Medical School, McLean Hospital, 115 Mill Street, Belmont, MA 02478 USA
| | - Oanh T. Luc
- grid.38142.3c000000041936754XHarvard Medical School, McLean Hospital, 115 Mill Street, Belmont, MA 02478 USA
| | - David Potter
- grid.38142.3c000000041936754XHarvard Medical School, McLean Hospital, 115 Mill Street, Belmont, MA 02478 USA
| | - Stefanie Nickels
- grid.38142.3c000000041936754XHarvard Medical School, McLean Hospital, 115 Mill Street, Belmont, MA 02478 USA
| | - Jack Bergman
- grid.38142.3c000000041936754XHarvard Medical School, McLean Hospital, 115 Mill Street, Belmont, MA 02478 USA
| | - William A. Carlezon
- grid.38142.3c000000041936754XHarvard Medical School, McLean Hospital, 115 Mill Street, Belmont, MA 02478 USA
| | - Diego A. Pizzagalli
- grid.38142.3c000000041936754XHarvard Medical School, McLean Hospital, 115 Mill Street, Belmont, MA 02478 USA
| |
Collapse
|
18
|
Berro LF, Overton JS, Reeves-Darby JA, Rowlett JK. Alprazolam-induced EEG spectral power changes in rhesus monkeys: a translational model for the evaluation of the behavioral effects of benzodiazepines. Psychopharmacology (Berl) 2021; 238:1373-1386. [PMID: 33594504 PMCID: PMC8177744 DOI: 10.1007/s00213-021-05793-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/09/2020] [Accepted: 02/04/2021] [Indexed: 12/23/2022]
Abstract
RATIONALE Benzodiazepines induce electroencephalography (EEG) changes in rodents and humans that are associated with distinct behavioral effects and have been proposed as quantitative biomarkers for GABAA receptor modulation. Specifically, central EEG beta and occipital EEG delta activity have been associated with anxiolysis and sedation, respectively. The extent to which nonhuman primates show the same dose- and topography-dependent effects remained unknown. OBJECTIVES We aimed at establishing a nonhuman primate model for the evaluation of benzodiazepine EEG pharmacology. METHODS Four adult male rhesus monkeys were prepared with fully implantable telemetry devices that monitored activity, peripheral body temperature, and contained two EEG (central and occipital), one electromyography (EMG), and one electrooculography channel. We investigated daytime alprazolam-induced changes in EEG spectral power, sleep-wake states, EMG activity, locomotor activity, and body temperature. Alprazolam (0.01-1.8 mg/kg, i.m.) or vehicle was administered acutely, and telemetry recording was conducted for 1 h. RESULTS Daytime alprazolam dose-dependently increased central EEG power (including beta activity), increased occipital EEG delta power, and decreased occipital EEG alpha, theta, and sigma power. There was an ~8-fold difference in the potency of alprazolam to increase central EEG beta vs. occipital EEG delta activity (based on relative EEG power). The highest dose, which increased both central EEG beta and occipital EEG delta relative power, induced sedative effects (increased time spent in N1 and N2 sleep stages) and decreased peripheral body temperature and locomotor activity. CONCLUSIONS Alprazolam induces dose- and topography-dependent EEG changes in rhesus monkeys and provides a valuable model for studying benzodiazepine pharmacology.
Collapse
Affiliation(s)
- Lais F. Berro
- Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 N State St, Jackson, MS, USA, 39216,Corresponding Author: Lais F. Berro, Ph.D., Department of Psychiatry & Human Behavior, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216,
| | - John S. Overton
- Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 N State St, Jackson, MS, USA, 39216
| | - Jaren A. Reeves-Darby
- Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 N State St, Jackson, MS, USA, 39216
| | - James K. Rowlett
- Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 N State St, Jackson, MS, USA, 39216
| |
Collapse
|
19
|
Beuckmann CT, Suzuki H, Musiek ES, Ueno T, Sato T, Bando M, Osada Y, Moline M. Evaluation of SAMP8 Mice as a Model for Sleep-Wake and Rhythm Disturbances Associated with Alzheimer's Disease: Impact of Treatment with the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant. J Alzheimers Dis 2021; 81:1151-1167. [PMID: 33843668 PMCID: PMC8293654 DOI: 10.3233/jad-201054] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Background: Many patients with Alzheimer’s disease (AD) display circadian rhythm and sleep-wake disturbances. However, few mouse AD models exhibit these disturbances. Lemborexant, a dual orexin receptor antagonist, is under development for treating circadian rhythm disorders in dementia. Objective: Evaluation of senescence-accelerated mouse prone-8 (SAMP8) mice as a model for sleep-wake and rhythm disturbances in AD and the effect of lemborexant by assessing sleep-wake/diurnal rhythm behavior. Methods: SAMP8 and control senescence-accelerated mouse resistant-1 (SAMR1) mice received vehicle or lemborexant at light onset; plasma lemborexant and diurnal cerebrospinal fluid (CSF) orexin concentrations were assessed. Sleep-wake behavior and running wheel activity were evaluated. Results: Plasma lemborexant concentrations were similar between strains. The peak/nadir timing of CSF orexin concentrations were approximately opposite between strains. During lights-on, SAMP8 mice showed less non-rapid eye movement (non-REM) and REM sleep than SAMR1 mice. Lemborexant treatment normalized wakefulness/non-REM sleep in SAMP8 mice. During lights-off, lemborexant-treated SAMR1 mice showed increased non-REM sleep; lemborexant-treated SAMP8 mice displayed increased wakefulness. SAMP8 mice showed differences in electroencephalogram architecture versus SAMR1 mice. SAMP8 mice exhibited more running wheel activity during lights-on. Lemborexant treatment reduced activity during lights-on and increased activity in the latter half of lights-off, demonstrating a corrective effect on overall diurnal rhythm. Lemborexant delayed the acrophase of activity in both strains by approximately 1 hour. Conclusion: SAMP8 mice display several aspects of sleep-wake and rhythm disturbances in AD, notably mistimed activity. These findings provide some preclinical rationale for evaluating lemborexant in patients with AD who experience sleep-wake and rhythm disturbances.
Collapse
Affiliation(s)
| | | | - Erik S Musiek
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
| | | | | | | | | | | |
Collapse
|
20
|
Kim JS, Kim S, Lee HS, Kwon YJ, Lee HY, Shim SH. Auditory evoked potentials and suicidal behaviors in patients with major depressive disorders. Sci Rep 2021; 11:7255. [PMID: 33790320 PMCID: PMC8012352 DOI: 10.1038/s41598-021-86602-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Accepted: 03/15/2021] [Indexed: 11/09/2022] Open
Abstract
Loudness dependence of auditory evoked potentials (LDAEP) has been proposed as a biological marker of central serotonergic activity related to suicides. This study’s objective was to analyze the difference in LDAEP between depressed patients with suicide attempts (SA) and suicidal ideation (SI). It included 130 participants (45 depressed patients with SA, 49 depressed patients with SI, and 36 healthy controls) aged > 18 years who exhibited LDAEP during electroencephalography. Psychological characteristics and event-related potentials of the three groups were compared. There was no significant difference in LDAEP between major depressive disorder (MDD) patients with SA and SI (p = 0.59). MDD patients with SI, who attempted suicide had significantly lower LDAEP than healthy controls (p = 0.01 and p = 0.01, respectively). However, the significance disappeared when psychological characteristics were controlled. Our results suggest that LDAEP might not be possible biomarkers for suicidal behaviors in patients with MDD. Further studies to assess the biological basis of suicide and identify the underlying dimensions that mediate the relationship between the biological basis and suicidal behaviors will be needed.
Collapse
Affiliation(s)
- Ji Sun Kim
- Department of Psychiatry, College of Medicine, Soonchunhyang University Cheonan Hospital, 31 Suncheonhyang 6-gil, Dongnam-gu, Cheonan, 31151, Republic of Korea
| | - Sungkean Kim
- Department of Human-Computer Interaction, Hanyang University, Ansan-si, 15588, South Korea
| | - Ho-Sung Lee
- Department of Pulmonology and Allergy, Cheonan Hospital, Soonchunhyang University, Cheonan, Republic of Korea
| | - Young Joon Kwon
- Department of Psychiatry, College of Medicine, Soonchunhyang University Cheonan Hospital, 31 Suncheonhyang 6-gil, Dongnam-gu, Cheonan, 31151, Republic of Korea
| | - Hwa Young Lee
- Department of Psychiatry, College of Medicine, Soonchunhyang University Cheonan Hospital, 31 Suncheonhyang 6-gil, Dongnam-gu, Cheonan, 31151, Republic of Korea
| | - Se-Hoon Shim
- Department of Psychiatry, College of Medicine, Soonchunhyang University Cheonan Hospital, 31 Suncheonhyang 6-gil, Dongnam-gu, Cheonan, 31151, Republic of Korea.
| |
Collapse
|
21
|
Konopka LM, Glowacki A, Konopka CJ, Wuest R. Objective Assessments in Diagnoses and Treatment: A Proposed Change in Paradigm. Clin EEG Neurosci 2021; 52:90-97. [PMID: 33370217 DOI: 10.1177/1550059420983998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
For patients with psychiatric disorders, current diagnostic and treatment approaches are far from optimal. The clinical interview drives the standard approach-matching symptoms to diagnostic criteria-and results in standardized pharmacological and behavioral treatments, often, with inadequate outcome; but now, recent imaging advances can correlate behavioral assessments with brain function and measure them against normative databases to provide data critical for the reevaluation of patient diagnosis and treatment. This article addresses the data that support a redefinition of our current paradigm. We believe a neurobehavioral approach provides for more personalized treatment approaches unbound from classically defined diagnostic biases.
Collapse
Affiliation(s)
| | | | - Christian J Konopka
- Department of Bioengineering, 14589University of Illinois at Urbana-Champaign, Urbana, IL, USA.,97472Beckman Institute for Advanced Science and Technology, Urbana, IL, USA.,43988University of Illinois College of Medicine, Urbana, IL, USA
| | - Ronald Wuest
- Institute for Personal Development, Romeiville, IL, USA
| |
Collapse
|
22
|
Fisher AS, Lanigan MT, Upton N, Lione LA. Preclinical Neuropathic Pain Assessment; the Importance of Translatability and Bidirectional Research. Front Pharmacol 2021; 11:614990. [PMID: 33628181 PMCID: PMC7897667 DOI: 10.3389/fphar.2020.614990] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2020] [Accepted: 12/10/2020] [Indexed: 02/04/2023] Open
Abstract
For patients suffering with chronic neuropathic pain the need for suitable novel therapies is imperative. Over recent years a contributing factor for the lack of development of new analgesics for neuropathic pain has been the mismatch of primary neuropathic pain assessment endpoints in preclinical vs. clinical trials. Despite continuous forward translation failures across diverse mechanisms, reflexive quantitative sensory testing remains the primary assessment endpoint for neuropathic pain and analgesia in animals. Restricting preclinical evaluation of pain and analgesia to exclusively reflexive outcomes is over simplified and can be argued not clinically relevant due to the continued lack of forward translation and failures in the clinic. The key to developing new analgesic treatments for neuropathic pain therefore lies in the development of clinically relevant endpoints that can translate preclinical animal results to human clinical trials. In this review we discuss this mismatch of primary neuropathic pain assessment endpoints, together with clinical and preclinical evidence that supports how bidirectional research is helping to validate new clinically relevant neuropathic pain assessment endpoints. Ethological behavioral endpoints such as burrowing and facial grimacing and objective measures such as electroencephalography provide improved translatability potential together with currently used quantitative sensory testing endpoints. By tailoring objective and subjective measures of neuropathic pain the translatability of new medicines for patients suffering with neuropathic pain will hopefully be improved.
Collapse
Affiliation(s)
- Amy S. Fisher
- Transpharmation Ltd., The London Bioscience Innovation Centre, London, United Kingdom
| | - Michael T. Lanigan
- Transpharmation Ltd., The London Bioscience Innovation Centre, London, United Kingdom
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom
| | - Neil Upton
- Transpharmation Ltd., The London Bioscience Innovation Centre, London, United Kingdom
| | - Lisa A. Lione
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom
| |
Collapse
|
23
|
Lee HS, Baik SY, Kim YW, Kim JY, Lee SH. Prediction of Antidepressant Treatment Outcome Using Event-Related Potential in Patients with Major Depressive Disorder. Diagnostics (Basel) 2020; 10:diagnostics10050276. [PMID: 32375213 PMCID: PMC7277962 DOI: 10.3390/diagnostics10050276] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2020] [Revised: 04/23/2020] [Accepted: 05/01/2020] [Indexed: 12/22/2022] Open
Abstract
(1) Background: Prediction of treatment outcome has been one of the core objectives in clinical research of patients with major depressive disorder (MDD). This study explored the possibility of event-related potential (ERP) markers to predict antidepressant treatment outcomes among MDD patients; (2) Methods: Fifty-two patients with MDD were recruited and evaluated through Hamilton depression (HAM-D), Hamilton anxiety rating scale (HAM-A), and CORE. Patients underwent a battery of ERP measures including frontal alpha symmetry (FAA) in the low alpha band (8–10 Hz), mismatch negativity (MMN), and loudness-dependent auditory evoked potentials (LDAEP); (3) Results: During the eight weeks of study, 61% of patients achieved remission, and 77% showed successful treatment responsiveness. Patients with low FAA in F5/F6 demonstrated a significantly higher remission/response ratio and better treatment responsiveness (F (2.560, 117.755) = 3.84, p = 0.016) compared to patients with high FAA. In addition, greater FAA in F7/F8 EEG channels was significantly associated with greater melancholia scores (r = 0.34, p = 0.018). Other ERP markers lacked any significant effect; (4) Conclusions: Our results suggested low FAA (i.e., greater left frontal activity) could reflect a good treatment response in MDD patients. These findings support that FAA could be a promising index in understanding both MDD and melancholic subtype.
Collapse
Affiliation(s)
- Hyun Seo Lee
- Clinical Emotion and Cognition Research Laboratory, Inje University, Goyang 50834, Korea; (H.S.L.); (S.Y.B.); (Y.-W.K.); (J.-Y.K.)
| | - Seung Yeon Baik
- Clinical Emotion and Cognition Research Laboratory, Inje University, Goyang 50834, Korea; (H.S.L.); (S.Y.B.); (Y.-W.K.); (J.-Y.K.)
| | - Yong-Wook Kim
- Clinical Emotion and Cognition Research Laboratory, Inje University, Goyang 50834, Korea; (H.S.L.); (S.Y.B.); (Y.-W.K.); (J.-Y.K.)
- Department of Biomedical Engineering, Hanyang University, Seoul 04763, Korea
| | - Jeong-Youn Kim
- Clinical Emotion and Cognition Research Laboratory, Inje University, Goyang 50834, Korea; (H.S.L.); (S.Y.B.); (Y.-W.K.); (J.-Y.K.)
| | - Seung-Hwan Lee
- Clinical Emotion and Cognition Research Laboratory, Inje University, Goyang 50834, Korea; (H.S.L.); (S.Y.B.); (Y.-W.K.); (J.-Y.K.)
- Department of Psychiatry, Inje University, Ilsan-Paik Hospital, Goyang 50834, Korea
- Correspondence: or ; Tel.: +82-31-910-7260; Fax: +82-31-910-7268
| |
Collapse
|
24
|
Raith H, Schuelert N, Duveau V, Roucard C, Plano A, Dorner-Ciossek C, Ferger B. Differential effects of traxoprodil and S-ketamine on quantitative EEG and auditory event-related potentials as translational biomarkers in preclinical trials in rats and mice. Neuropharmacology 2020; 171:108072. [PMID: 32243874 DOI: 10.1016/j.neuropharm.2020.108072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Revised: 02/14/2020] [Accepted: 03/25/2020] [Indexed: 12/16/2022]
Abstract
Quantitative Electroencephalography (qEEG) and event-related potential (ERP) assessment have emerged as powerful tools to unravel translational biomarkers in preclinical and clinical psychiatric drug discovery trials. The aim of the present study was to compare the GluN2B negative allosteric modulator (NAM) traxoprodil (CP-101,606) with the unselective NMDA receptor channel blocker S-ketamine to give insight into central target engagement and differentiation on multiple EEG readouts. For qEEG recordings telemetric transmitters were implanted in male Wistar rats. Recorded EEG data were analyzed using fast Fourier transformation to determine power spectra and vigilance states. Additionally, body temperature and locomotor activity were assessed via telemetry. For recordings of auditory event-related potentials (AERP) male C57Bl/6J mice were chronically implanted with deep electrodes using a tethered system. Power spectral analysis revealed a significant increase in gamma power following ketamine treatment, whereas traxoprodil (6&18 mg/kg) induced an overall decrease primarily within alpha and beta bands. Additionally, ketamine disrupted sleep and enhanced time spent in wake vigilance states, whereas traxoprodil did not alter sleep-wake architecture. AERP and mismatch negativity (MMN) revealed that ketamine (10 mg/kg) selectively disrupts auditory deviance detection, whereas traxoprodil (6 mg/kg) did not alter MMN at clinically relevant doses. In contrast to ketamine treatment, traxoprodil did not produce hyperactivity and hypothermia. In conclusion, ketamine and traxoprodil showed very different effects on diverse EEG readouts differentiating selective GluN2B antagonism from non-selective pan-NMDA-R antagonists like ketamine. These readouts are thus perfectly suited to support drug discovery efforts on NMDA-R and understanding the different functions of NMDA-R subtypes.
Collapse
Affiliation(s)
- Henrike Raith
- Boehringer Ingelheim Pharma GmbH & Co. KG, CNS Diseases Research Germany, Birkendorferstr. 65, 88397, Biberach an der Riß, Germany.
| | - Niklas Schuelert
- Boehringer Ingelheim Pharma GmbH & Co. KG, CNS Diseases Research Germany, Birkendorferstr. 65, 88397, Biberach an der Riß, Germany.
| | - Venceslas Duveau
- SynapCell SAS, Biopolis and Institut Jean Roget, Université Joseph Fourier-Grenoble 1, Domaine de la merci, 38700, La Tronche, France.
| | - Corinne Roucard
- SynapCell SAS, Biopolis and Institut Jean Roget, Université Joseph Fourier-Grenoble 1, Domaine de la merci, 38700, La Tronche, France.
| | - Andrea Plano
- Plano Consulting, Georg-Schinbain-Str. 70, 88400, Biberach an der Riß, Germany.
| | - Cornelia Dorner-Ciossek
- Boehringer Ingelheim Pharma GmbH & Co. KG, CNS Diseases Research Germany, Birkendorferstr. 65, 88397, Biberach an der Riß, Germany.
| | - Boris Ferger
- Boehringer Ingelheim Pharma GmbH & Co. KG, CNS Diseases Research Germany, Birkendorferstr. 65, 88397, Biberach an der Riß, Germany.
| |
Collapse
|
25
|
Methods in Electrode Implantation and Wiring for Long-Term Continuous EEG Monitoring in Rodent Models of Epilepsy and Behavioral Disturbances. Methods Mol Biol 2020; 2011:429-439. [PMID: 31273714 DOI: 10.1007/978-1-4939-9554-7_25] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/06/2023]
Abstract
Rodent seizure models that pathologically and behaviorally recapitulate age-tailored epileptic disorders are used by us and others to advance our understanding of the chronobiology and mechanisms of epileptic seizure emergence and their comorbidities and to investigate potential novel treatment strategies. Obtaining prolonged continuous electroencephalogram (EEG) tracings over months is essential in this line of translational research, particularly to assess the relation between electrographic changes and the development of seizures and their various psychiatric and cognitive comorbidities in models where seizures gradually emerge over weeks following brain insults. Here we describe our approach to electrode implantation and wiring in order to successfully obtain high-quality continuous EEG tracings in rats for prolonged periods. A detailed stepwise methodological description is provided with a special focus on the details that help most in avoiding notorious pitfalls such as premature EEG cable disconnections and a poor signal to noise ratio.
Collapse
|
26
|
Fernández-Palleiro P, Rivera-Baltanás T, Rodrigues-Amorim D, Fernández-Gil S, Del Carmen Vallejo-Curto M, Álvarez-Ariza M, López M, Rodriguez-Jamardo C, Luis Benavente J, de Las Heras E, Manuel Olivares J, Spuch C. Brainwaves Oscillations as a Potential Biomarker for Major Depression Disorder Risk. Clin EEG Neurosci 2020; 51:3-9. [PMID: 31537100 DOI: 10.1177/1550059419876807] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Major depressive disorder (MDD) is a multidimensional disorder that is characterized by the presence of alterations in mood, cognitive capacity, sensorimotor, and homeostatic functions. Given that about half of the patients diagnosed with MDD do not respond to the various current treatments, new techniques are being sought to predict not only the course of the disease but also the characteristics that differentiate responders from non-responders. Using the electroencephalogram, a noninvasive and inexpensive tool, most studies have proposed that patients with MDD have some lateralization in brain electrical activity, with alterations in alpha and theta rhythms being observed, which would be related to dysfunctions in emotional capacity such as the absence or presence of responses to the different existing treatments. These alterations help in the identification of subjects at high risk of suffering from depression, in the differentiation into responders and nonresponders to various therapies (pharmacological, electroconvulsive therapy, and so on), as well as to establish in which period of the disease the treatment will be more effective. Although the data are still inconclusive and more research is needed, these alpha and theta neurophysiological markers could support future clinical practice when it comes to establishing an early diagnosis and treating state disorders more successfully and accurately of mood disorders.
Collapse
Affiliation(s)
- Patricia Fernández-Palleiro
- Translational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, Cibersam, Spain
| | - Tania Rivera-Baltanás
- Translational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, Cibersam, Spain
| | - Daniela Rodrigues-Amorim
- Translational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, Cibersam, Spain
| | - Sonia Fernández-Gil
- Translational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, Cibersam, Spain
| | | | - María Álvarez-Ariza
- Translational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, Cibersam, Spain
| | - Marta López
- Translational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, Cibersam, Spain
| | - Cynthia Rodriguez-Jamardo
- Translational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, Cibersam, Spain
| | - Jose Luis Benavente
- Translational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, Cibersam, Spain
| | - Elena de Las Heras
- Translational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, Cibersam, Spain
| | - José Manuel Olivares
- Translational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, Cibersam, Spain
| | - Carlos Spuch
- Translational Neuroscience Research Group, Galicia Sur Health Research Institute, University of Vigo, Cibersam, Spain
| |
Collapse
|
27
|
What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. Neurobiol Aging 2020; 85:58-73. [DOI: 10.1016/j.neurobiolaging.2019.09.008] [Citation(s) in RCA: 77] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Revised: 08/27/2019] [Accepted: 09/14/2019] [Indexed: 01/14/2023]
|
28
|
Dharmadhikari AS, Jaiswal SV, Tandle AL, Sinha D, Jog N. Study of Frontal Alpha Asymmetry in Mild Depression: A Potential Biomarker or Not? J Neurosci Rural Pract 2019; 10:250-255. [PMID: 31001013 PMCID: PMC6454961 DOI: 10.4103/jnrp.jnrp_293_18] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Background: Depression, despite being the most common of mental illness lacks any quantifiable and absolute biomarker. Frontal alpha asymmetry (FAA) is proposed as biomarker of depression both in resting and activated state. Yet, the location of extraction of alpha, clinical utility as well as validity of FAA is uncertain. With aim of obtaining clarity on this confusion we conducted this study. Methodology: Electroencephalographic frontal alpha power was calculated in patients of depression (n = 24) and compared with healthy controls (n = 17) for the assessment of FAA. Both groups were studied for resting phase and activation phase changes in FAA. For activation phase, auditory stimuli in the form of Indian classical music were used. Results: Frontal alpha power was measured across FP1, FP2, F3, F4, F7, and F8. Mean powers were compared in resting (before), activated (during) and postactivated resting stage (after). FAA was statistically significant in F7–F8 pair of electrodes and on F7 electrode when compared between cases and controls. Conclusion: Quest for biomarker for depression churned out FAA as frontrunner. Despite of vast amount of research on it, practical utility eludes us. We need to revisit our approach from conventional search of the diagnostic biomarker; as FAA might reflect component of depression but not totally disorder. In our opinion, we are not yet ready for it and have a road ahead to travel.
Collapse
Affiliation(s)
- Ambrish S Dharmadhikari
- Department of Psychiatry, H. B. T. Medical College and Dr. R. N. Cooper Mun. Gen. Hospital, Mumbai, Maharashtra, India
| | - Suyog Vijay Jaiswal
- Department of Psychiatry, H. B. T. Medical College and Dr. R. N. Cooper Mun. Gen. Hospital, Mumbai, Maharashtra, India
| | - Avinash L Tandle
- Department of Electronics and Telecommunication, Mukesh Patel School of Technology, Management and Engineering, NMIMS University, Mumbai, Maharashtra, India
| | - Deoraj Sinha
- Department of Psychiatry, H. B. T. Medical College and Dr. R. N. Cooper Mun. Gen. Hospital, Mumbai, Maharashtra, India
| | - Nandini Jog
- Department of Electronics and Telecommunication, Mukesh Patel School of Technology, Management and Engineering, NMIMS University, Mumbai, Maharashtra, India
| |
Collapse
|
29
|
Kim JS, Kim DW, Kwon YJ, Lee HY, Kim S, Shim SH. The relationship between auditory evoked potentials and symptoms of attention-deficit/hyperactivity disorder in adult patients with major depressive disorder. Int J Psychophysiol 2019; 142:50-56. [PMID: 31207261 DOI: 10.1016/j.ijpsycho.2019.06.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2019] [Revised: 06/10/2019] [Accepted: 06/13/2019] [Indexed: 12/25/2022]
Abstract
OBJECTIVES Loudness dependence of auditory evoked potential (LDAEP) has been proposed as a biological marker for central serotonergic activity in depressive illness. A recent study has suggested that serotonin plays an important role in impulsivity and emotional sensitivity that are prominent clinical manifestations in attention deficit and hyperactivity disorder (ADHD). The objective of this study was to examine the association between LDAEP and ADHD symptoms in major depressive disorder (MDD). METHODS A total of 60 participants (40 subjects with MDD and 20 healthy controls) aged >18 years who had LDAEPs performed during electroencephalograms were included in this study. ADHD symptoms, depressive, and anxiety symptoms were evaluated. Psychological characteristics and event-related potentials (ERP) were compared among three groups: depression with ADHD symptoms, depression without ADHD symptoms, and healthy controls. RESULTS MDD subjects with ADHD symptoms (N = 20) showed significantly lower LDAEP levels than those without ADHD symptoms (N = 20) and healthy controls (N = 20). LDAEP differences between MDD subjects without ADHD symptoms and healthy controls were not statistically significant. In partial correlation analyses adjusted for age and sex, significant correlations of psychological scales of depression, ADHD symptoms, and LDAEPs were found. CONCLUSION Results of the present study suggest that LDAEP can reflect adult ADHD symptoms in MDD. Auditory evoked potential appears to be a promising candidate as an evaluation tool for inattention and poor impulse control as well as emotional sensitivity.
Collapse
Affiliation(s)
- Ji Sun Kim
- Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea
| | - Do-Won Kim
- Department of Biomedical Engineering, Chonnam National University, Yeosu, Republic of Korea
| | - Young Joon Kwon
- Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea
| | - Hwa Young Lee
- Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea
| | - Sungkean Kim
- Department of Biomedical Engineering, Hanyang University, Seoul, Republic of Korea
| | - Se Hoon Shim
- Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea.
| |
Collapse
|
30
|
Li F, Egawa N, Yoshimoto S, Mizutani H, Kobayashi K, Tachibana N, Takahashi R. Potential Clinical Applications and Future Prospect of Wireless and Mobile Electroencephalography on the Assessment of Cognitive Impairment. Bioelectricity 2019; 1:105-112. [PMID: 34471813 DOI: 10.1089/bioe.2019.0001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Electroencephalography (EEG) systems have been used for assessing cognitive function in dementia for several decades. Studies have demonstrated that EEG in Alzheimer's disease (AD) patients is generally characterized by significant and specific increases in delta and theta power, a decrease in alpha power, and a decrease in the coherence of the fast bands between different brain areas linked by long corticocortical fibers. Posterior EEG characteristics in dementia with Lewy bodies (DLB) allowed discrimination of DLB from AD and controls with high accuracy. Traditional EEG systems require a long application time and discomfort, which limited its use in dementia patients. Alternative tools for assessing cognition may be simple, low-cost, and mobile medical devices such as wireless and mobile EEG (wmEEG) sensor platforms with flexible electronics and stretchable electrode sheets that could be compatible with long-term EEG monitoring even in dementia patients. In this study, we review the utility of EEG in reflecting cognitive function and the prospects for clinical application of wmEEG monitoring for detecting early dementia and discriminating subtypes of dementia effectively and objectively assessing longitudinal cognitive changes. Repeated and longitudinal documentation of EEG using wmEEG will contribute to detection of specific sleep/wake EEG patterns for patients with sleep and wake-related problems related to dementia.
Collapse
Affiliation(s)
- Fangzhou Li
- Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Naohiro Egawa
- Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | | | | | - Katsuya Kobayashi
- Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Naoko Tachibana
- Department of Neurology, Center for Sleep-Related Disorders, Kansai Electric Power Hospital, Osaka, Japan
| | - Ryosuke Takahashi
- Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| |
Collapse
|
31
|
Crouch B, Yeap JM, Pais B, Riedel G, Platt B. Of mice and motion: Behavioural-EEG phenotyping of Alzheimer’s disease mouse models. J Neurosci Methods 2019; 319:89-98. [DOI: 10.1016/j.jneumeth.2018.06.028] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2018] [Revised: 06/14/2018] [Accepted: 06/28/2018] [Indexed: 01/22/2023]
|
32
|
Devilbiss DM, Etnoyer-Slaski JL, Dunn E, Dussourd CR, Kothare MV, Martino SJ, Simon AJ. Effects of Exercise on EEG Activity and Standard Tools Used to Assess Concussion. JOURNAL OF HEALTHCARE ENGINEERING 2019; 2019:4794637. [PMID: 31183030 PMCID: PMC6515073 DOI: 10.1155/2019/4794637] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/01/2018] [Revised: 03/18/2019] [Accepted: 04/01/2019] [Indexed: 12/19/2022]
Abstract
A variety of cognitive assessment tools are used to determine the functional status of the brain before and after injury in athletes. Questionnaires, neuropsychological tests, and electroencephalographic (EEG) measures have been recently used to directly assess brain function on and near the playing field. However, exercise can affect cognitive performance and EEG measures of cortical activity. To date, little empirical evidence exists on the effects of acute exercise on these measures of neurological function. We therefore quantified athlete performance on a standardized battery of concussion assessment tools and EEG measurements immediately before and after acute exercise to simulate conditions of athletic competition. Heart rate and arterial oxygen levels were collected before and after the exercise challenge consisting of a 1-mile run. Together these data, from a gender-balanced cohort of collegiate athletes, demonstrated that moderate to hard levels of acute exercise improved performance on the King-Devick test (K-D test) and Standardized Assessment of Concussion (SAC) component of the Sport Concussion Assessment Tool (SCAT3). Gender played an important role in these effects, and performance was most affected by exercise in female athletes. EEG activity in the theta band (4-8 Hz) was decreased during periods of quiet resting with eyes open or eyes closed. Additionally, exercise produced a slowing of the EEG during the K-D test and a shift to higher frequencies during the balance assessment of the SCAT3. Together, these data indicate that exercise alone can influence outcome measures of cognitive assessment tools used to assess brain function in athletes. Finally, care must be taken to acquire postinjury measurements during a comparable physiologic state to that in which baseline assessment data were measured, and further research is needed into the factors influencing outcome measures of these tests.
Collapse
Affiliation(s)
- David M. Devilbiss
- Rowan University, Department of Cell Biology and Neuroscience, 2 Medical Center Drive, SC220, Stratford, NJ 08084, USA
| | - Jena L. Etnoyer-Slaski
- Lehigh University, Department of Sports Medicine, 641 Taylor Street, Bethlehem, PA 18015, USA
| | - Emily Dunn
- Lehigh University, Department of Sports Medicine, 641 Taylor Street, Bethlehem, PA 18015, USA
| | - Christopher R. Dussourd
- Lehigh University, Department of Sports Medicine, 641 Taylor Street, Bethlehem, PA 18015, USA
| | - Mayuresh V. Kothare
- Lehigh University, Department of Chemical & Biomolecular Engineering, B323/D322 Iacocca Hall, 111 Research Drive, Bethlehem, PA 18015, USA
| | - Stephen J. Martino
- Monmouth-Ocean Neurology, 1944 State Route 33, Suite 206, Neptune, NJ 07753, USA
| | - Adam J. Simon
- Cerora Inc., 116 Research Drive, Bethlehem, PA 18015, USA
| |
Collapse
|
33
|
TAK-071, a muscarinic M1 receptor positive allosteric modulator, attenuates scopolamine-induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys. PLoS One 2019; 14:e0207969. [PMID: 30856192 PMCID: PMC6411103 DOI: 10.1371/journal.pone.0207969] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Accepted: 02/26/2019] [Indexed: 12/22/2022] Open
Abstract
Activation of the muscarinic M1 receptor is a promising approach to improve cognitive deficits associated with cholinergic dysfunction in Alzheimer’s disease, dementia with Lewy bodies, and schizophrenia. TAK-071 is an M1-selective positive allosteric modulator that improves cognitive deficits induced by scopolamine, a non-selective muscarinic receptor antagonist, with reduced side effects on gastrointestinal function in rats. In this study, we explored changes in quantitative electroencephalography (qEEG) power bands, with or without scopolamine challenge, as a non-invasive translational biomarker for the effect of TAK-071 in cynomolgus monkeys. Scopolamine has been reported to increase theta and delta power bands and decrease alpha power band in healthy volunteers. In line with the clinical observations, scopolamine (25–100 μg/kg, subcutaneous administration [s.c.]) increased theta and delta power bands in cynomolgus monkeys in a dose-dependent manner, whereas it had the opposite effect on alpha power band. The effects of TAK-071 on scopolamine (25 μg/kg, s.c.)-induced qEEG spectral changes were examined using an acetylcholinesterase inhibitor donepezil and a muscarinic M1/M4 receptor agonist xanomeline as comparative cholinomimetics. TAK-071 (0.3–3 mg/kg, oral administration [p.o.]), donepezil (3 mg/kg, p.o.), and xanomeline (1 mg/kg, s.c.) suppressed the scopolamine-induced increases in alpha, theta, and delta power bands. These results suggest that changes in specific qEEG power bands, in particular theta and delta power bands in the context of scopolamine challenge, could be used as translational biomarkers for the evaluation of TAK-071 in clinical studies.
Collapse
|
34
|
Medlej Y, Asdikian R, Wadi L, Salah H, Dosh L, Hashash R, Karnib N, Medlej M, Darwish H, Kobeissy F, Obeid M. Enhanced setup for wired continuous long-term EEG monitoring in juvenile and adult rats: application for epilepsy and other disorders. BMC Neurosci 2019; 20:8. [PMID: 30832562 PMCID: PMC6398261 DOI: 10.1186/s12868-019-0490-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Accepted: 02/26/2019] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND The electroencephalogram (EEG) is a widely used laboratory technique in rodent models of epilepsy, traumatic brain injury (TBI), and other neurological diseases accompanied by seizures. Obtaining prolonged continuous EEG tracings over weeks to months is essential to adequately answer research questions related to the chronobiology of seizure emergence, and to the effect of potential novel treatment strategies. Current EEG recording methods include wired and the more recent but very costly wireless technologies. Wired continuous long-term EEG in rodents remains the mainstay approach but is often technically challenging due to the notorious frequent EEG cable disconnections from the rodent's head, and to poor signal-to-noise ratio especially when simultaneously monitoring multiple animals. Premature EEG cable disconnections and cable movement-related artifacts result from the animal's natural mobility, and subsequent tension on the EEG wires, as well as from potential vigorous and frequent seizures. These challenges are often accompanied by injuries to the scalp, and result in early terminations of costly experiments. RESULTS Here we describe an enhanced customized swivel-balance EEG-cage system that allows tension-free rat mobility. The cage setup markedly improves the safety and longevity of current existing wired continuous long-term EEG. Prevention of EEG cable detachments is further enhanced by a special attention to surgical electrode anchoring to the skull. In addition to mechanically preventing premature disconnections, the detailed stepwise approach to the electrical shielding, wiring and grounding required for artifact-free high signal-to-noise ratio recordings is also included. The successful application of our EEG cage system in various rat models of brain insults and epilepsy is described with illustrative high quality tracings of seizures and electrographic patterns obtained during continuous and simultaneous monitoring of multiple rats early and up to 3 months post-brain insult. CONCLUSION Our simple-to-implement key modifications to the EEG cage setup allow the safe acquisition of substantial high quality wired EEG data without resorting to the still costly wireless technologies.
Collapse
Affiliation(s)
- Yasser Medlej
- Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Diana Tamari Sabbagh (DTS) Building, first floor, 117b, P.O. Box 11-0236, Riad El-Solh, Beirut, 1107 2020, Lebanon
| | - Rita Asdikian
- Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Diana Tamari Sabbagh (DTS) Building, first floor, 117b, P.O. Box 11-0236, Riad El-Solh, Beirut, 1107 2020, Lebanon
| | - Lara Wadi
- Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Houssein Salah
- Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Diana Tamari Sabbagh (DTS) Building, first floor, 117b, P.O. Box 11-0236, Riad El-Solh, Beirut, 1107 2020, Lebanon
| | - Laura Dosh
- Animal Care Facility, American University of Beirut, Beirut, Lebanon
| | - Rabih Hashash
- Animal Care Facility, American University of Beirut, Beirut, Lebanon
| | - Nabil Karnib
- Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Diana Tamari Sabbagh (DTS) Building, first floor, 117b, P.O. Box 11-0236, Riad El-Solh, Beirut, 1107 2020, Lebanon.,Department of Natural Sciences, School of Arts and Sciences, Lebanese American University, Byblos, Lebanon
| | | | - Hala Darwish
- Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Diana Tamari Sabbagh (DTS) Building, first floor, 117b, P.O. Box 11-0236, Riad El-Solh, Beirut, 1107 2020, Lebanon.,Rafic Hariri School of Nursing, American University of Beirut, Beirut, Lebanon
| | - Firas Kobeissy
- Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Makram Obeid
- Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Diana Tamari Sabbagh (DTS) Building, first floor, 117b, P.O. Box 11-0236, Riad El-Solh, Beirut, 1107 2020, Lebanon. .,Division of Child Neurology, Department of Pediatric and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
| |
Collapse
|
35
|
Assessing seizure liability using multi-electrode arrays (MEA). Toxicol In Vitro 2019; 55:93-100. [DOI: 10.1016/j.tiv.2018.12.001] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Revised: 12/03/2018] [Accepted: 12/03/2018] [Indexed: 12/20/2022]
|
36
|
Zanettini C, Scaglione A, Keighron JD, Giancola JB, Lin SC, Newman AH, Tanda G. Pharmacological classification of centrally acting drugs using EEG in freely moving rats: an old tool to identify new atypical dopamine uptake inhibitors. Neuropharmacology 2018; 161:107446. [PMID: 30481526 DOI: 10.1016/j.neuropharm.2018.11.034] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Revised: 11/05/2018] [Accepted: 11/23/2018] [Indexed: 10/27/2022]
Abstract
Atypical dopamine uptake inhibitors (DUIs) bind to the dopamine transporter and inhibit the reuptake of dopamine but have lower abuse potential than psychostimulants. Several atypical DUIs can block abuse-related effects of cocaine and methamphetamine, thus making them potential medication candidates for psychostimulant use disorders. The aim of the current study is to establish an in-vivo assay using EEG for the rapid identification of atypical DUIs with potential for medication development. The typical DUIs cocaine and methylphenidate dose-dependently decreased the power of the alpha, beta, and gamma bands. The atypical DUI modafinil and its F-analog, JBG1-049, decreased the power of beta, but in contrast to cocaine, none of the other frequency bands, while JHW007 did not significantly alter the EEG spectrum. The mu-opioid receptor agonists heroin and morphine dose-dependently decreased the power of gamma and increased power of the other bands. The effect of morphine on EEG power bands was antagonized by naltrexone. The NMDA receptor antagonist ketamine increased the power of all frequency bands. Therefore, typical and atypical DUIs and drugs of other classes differentially affected EEG spectra, showing distinctive features in the magnitude and direction of their effects on EEG. Comparative analysis of the effects of test drugs on EEG indicates a potential atypical profile of JBG1-049 with similar potency and effectiveness to its parent compound modafinil. These data suggest that EEG can be used to rapidly screen compounds for potential activity at specific pharmacological targets and provide valuable information for guiding the early stages of drug development. This article is part of the issue entitled 'Special Issue on Neurotransmitter Transporters'.
Collapse
Affiliation(s)
- Claudio Zanettini
- Medication Development Program, Molecular Targets and Medications Discovery Branch, NIDA-IRP, NIH/DHHS, Baltimore, MD, USA.
| | - Alessandro Scaglione
- Neural Circuits and Cognition Unit, Laboratory of Behavioral Neuroscience, NIA-IRP, NIH/DHHS, Baltimore, MD, USA
| | - Jacqueline D Keighron
- Medication Development Program, Molecular Targets and Medications Discovery Branch, NIDA-IRP, NIH/DHHS, Baltimore, MD, USA
| | - JoLynn B Giancola
- Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, NIDA-IRP, NIH/DHHS, Baltimore, MD, USA
| | - Shih-Chieh Lin
- Neural Circuits and Cognition Unit, Laboratory of Behavioral Neuroscience, NIA-IRP, NIH/DHHS, Baltimore, MD, USA
| | - Amy H Newman
- Medication Development Program, Molecular Targets and Medications Discovery Branch, NIDA-IRP, NIH/DHHS, Baltimore, MD, USA; Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, NIDA-IRP, NIH/DHHS, Baltimore, MD, USA
| | - Gianluigi Tanda
- Medication Development Program, Molecular Targets and Medications Discovery Branch, NIDA-IRP, NIH/DHHS, Baltimore, MD, USA
| |
Collapse
|
37
|
Stoiljkovic M, Kelley C, Horvath TL, Hajós M. Neurophysiological signals as predictive translational biomarkers for Alzheimer's disease treatment: effects of donepezil on neuronal network oscillations in TgF344-AD rats. Alzheimers Res Ther 2018; 10:105. [PMID: 30301466 PMCID: PMC6178257 DOI: 10.1186/s13195-018-0433-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2018] [Accepted: 09/17/2018] [Indexed: 12/20/2022]
Abstract
BACKGROUND Translational research in Alzheimer's disease (AD) pathology provides evidence that accumulation of amyloid-β and hyperphosphorylated tau, neuropathological hallmarks of AD, is associated with complex disturbances in synaptic and neuronal function leading to oscillatory abnormalities in the neuronal networks that support memory and cognition. Accordingly, our recent study on transgenic TgF344-AD rats modeling AD showed an age-dependent reduction of stimulation-induced oscillations in the hippocampus, and disrupted long-range connectivity together with enhanced neuronal excitability in the cortex, reflected in greatly increased expression of high-voltage spindles, an epileptic absence seizure-like activity. To better understand the translational value of observed oscillatory abnormalities in these rats, we examine here the effects of donepezil, an acetylcholine esterase inhibitor clinically approved for AD treatment. METHODS Brainstem nucleus pontis oralis stimulation-induced hippocampal oscillations were recorded under urethane anesthesia in adult (6-month-old) and aged (12-month-old) TgF344-AD and wild-type rats. Spontaneous cortical activity was monitored in a cohort of freely behaving aged rats implanted with frontal and occipital cortical electroencephalography (EEG) electrodes. RESULTS Subcutaneous administration of donepezil significantly augmented stimulation-induced hippocampal theta oscillation in aged wild-type rats and both adult and aged TgF344-AD rats, which have been previously shown to have diminished response to nucleus pontis oralis stimulation. Moreover, in adult TgF344-AD rats, donepezil also significantly increased theta phase-gamma amplitude coupling in the hippocampus during stimulation. However, neither of these effects were significantly changed in adult wild-type rats. Under freely behaving conditions, donepezil treatment had the opposite effect on cortical oscillatory connectivity in TgF344-AD and wild-type rats, and it reduced the occurrence of high-voltage spindle activity in TgF344-AD rats. CONCLUSIONS Together, these results imply that pharmacologically enhancing cholinergic tone with donepezil could partially reverse oscillatory abnormalities in TgF344-AD rats, which is in line with its clinical effectiveness in AD patients. Therefore, our study suggests good translational opportunities for these neurophysiological signals recorded in TgF344-AD rats, and their application could be considered in drug discovery efforts for developing therapies with disease-modifying potential.
Collapse
Affiliation(s)
- Milan Stoiljkovic
- Translational Neuropharmacology, Department of Comparative Medicine, Yale University School of Medicine, 310 Cedar St, New Haven, CT 06520 USA
| | - Craig Kelley
- Translational Neuropharmacology, Department of Comparative Medicine, Yale University School of Medicine, 310 Cedar St, New Haven, CT 06520 USA
| | - Tamas L. Horvath
- Translational Neuropharmacology, Department of Comparative Medicine, Yale University School of Medicine, 310 Cedar St, New Haven, CT 06520 USA
| | - Mihály Hajós
- Translational Neuropharmacology, Department of Comparative Medicine, Yale University School of Medicine, 310 Cedar St, New Haven, CT 06520 USA
| |
Collapse
|
38
|
Kaiser AK, Gnjezda MT, Knasmüller S, Aichhorn W. Electroencephalogram alpha asymmetry in patients with depressive disorders: current perspectives. Neuropsychiatr Dis Treat 2018; 14:1493-1504. [PMID: 29928121 PMCID: PMC6001846 DOI: 10.2147/ndt.s137776] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
PURPOSE Electroencephalogram (EEG) alpha asymmetry (AA) in depressive disorders has been of interest over the last few decades, but it continues to remain unclear whether EEG AA can discriminate between healthy and depressive individuals. MATERIALS AND METHODS A systematic literature search for papers addressing EEG AA using the keywords alpha asymmetry, depression, and EEG was performed in PubMed. All studies were checked for sample size, gender, handedness, reference, recording protocol, EEG band range, impedance, type of analysis, drugs, and comorbidity. RESULTS A total of 61 articles were found, of which 44 met our inclusion criteria. They have been consecutively analyzed in respect of methodology and results. Approximately 25% (11/44) of the studies did not mention or ignored handedness, 41% (18/44) of the studies used data with only self-reported handedness, and only 34.1% (15/44) of all studies tested handedness. Only 35% (15/44) of the studies reported pharmacological treatment, and only 35% (15/44) of the studies controlled for medication. A total of 52% (23/44) of the studies reported comorbidity, and only 30% (13/44) of the studies controlled for comorbidity. Only 29.6% (13/44) of the studies reported education. In all, 30.5% (13/44) of the studies analyzed group differences and correlations, while 15.9 (7/44) of the studies used only correlational analyses. A total of 52.3% (23/44) of the studies analyzed only group differences. Alpha range was fixed (8-13 Hz) in 59.1% (26/44) of all studies. Reference to common average was used in seven of 44 studies (15.9%). In all, nine of 44 (20.5%) studies used the midline central position as reference, 22 of 44 (50%) studies used the ear or the mastoid as reference, and four of 44 (9.1%) studies used the nose as reference. CONCLUSION Discriminative power of EEG AA for depressed and healthy controls remains unclear. A systematic analysis of 44 studies revealed that differences in methodology and disregarding proper sampling are problematic. Ignoring handedness, gender, age, medication, and comorbidity could explain inconsistent findings. Hence, we formulated a guideline for requirements for future studies on EEG AA in order to allow for better comparisons.
Collapse
Affiliation(s)
- Andreas Kurt Kaiser
- Department of Clinical Psychology, Salzburger Landeskliniken Betriebs-GesmbH, Christian-Doppler-Klinik, Paracelsus Medical University, Salzburg, Austria
| | - Maria-Theresa Gnjezda
- Department of Clinical Psychology, Salzburger Landeskliniken Betriebs-GesmbH, Christian-Doppler-Klinik, Paracelsus Medical University, Salzburg, Austria
| | - Stephanie Knasmüller
- Department of Clinical Psychology, Salzburger Landeskliniken Betriebs-GesmbH, Christian-Doppler-Klinik, Paracelsus Medical University, Salzburg, Austria
| | - Wolfgang Aichhorn
- Department of Psychiatry, Salzburger Landeskliniken Betriebs-GesmbH, Christian-Doppler-Klinik, Paracelsus Medical University, Salzburg, Austria
| |
Collapse
|
39
|
Hunter R. Developing tomorrow's antipsychotics: the need for a more personalised approach. ACTA ACUST UNITED AC 2018. [DOI: 10.1192/apt.bp.110.008235] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
SummaryThere has been little pharmacological advance in the treatment of schizophrenia since the introduction of chlorpromazine in the 1950s. This may be set to change as recent advances in molecular biology offer the prospect of a better understanding of the pathophysiology of the disorder and allow investigation of the complex interplay of genetic and environmental risk factors. In this review I discuss future approaches to antipsychotic drug development, highlighting the need to better define symptom areas and develop drugs based on an understanding of neurobiological mechanisms. The development of biomarkers has the potential in future to improve differential diagnosis and help predict response to treatment. These developments herald the possibility of a more integrated drug discovery approach and the subsequent provision of more stratified healthcare, and hopefully significant improvements in patient care and improved long-term outcomes.
Collapse
|
40
|
Tian Y, Yang L, Xu W, Zhang H, Wang Z, Zhang H, Zheng S, Shi Y, Xu P. Predictors for drug effects with brain disease: Shed new light from EEG parameters to brain connectomics. Eur J Pharm Sci 2017; 110:26-36. [PMID: 28456573 DOI: 10.1016/j.ejps.2017.04.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Revised: 04/24/2017] [Accepted: 04/24/2017] [Indexed: 01/21/2023]
Abstract
Though researchers spent a lot of effort to develop treatments for neuropsychiatric disorders, the poor translation of drug efficacy data from animals to human hampered the success of these therapeutic approaches in human. Pharmaceutical industry is challenged by low clinical success rates for new drug registration. To maximize the success in drug development, biomarkers are required to act as surrogate end points and predictors of drug effects. The pathology of brain disease could be in part due to synaptic dysfunction. Electroencephalogram (EEG), generating from the result of the postsynaptic potential discharge between cells, could be a potential measure to bridge the gaps between animal and human data. Here we discuss recent progress on using relevant EEG characteristics and brain connectomics as biomarkers to monitor drug effects and measure cognitive changes on animal models and human in real-time. It is expected that the novel approach, i.e. EEG connectomics, will offer a deeper understanding on the drug efficacy at a microcirculatory level, which will be useful to support the development of new treatments for neuropsychiatric disorders.
Collapse
Affiliation(s)
- Yin Tian
- Biomedical Engineering Department, Key Laboratory of Photoelectronic Information Sensing and Transmitting Technology, High School Innovation Team of Architecture and Core Technologies of Smart Medical System, ChongQing University of Posts and Telecommunications, ChongQing 400065, China.
| | - Li Yang
- Biomedical Engineering Department, Key Laboratory of Photoelectronic Information Sensing and Transmitting Technology, High School Innovation Team of Architecture and Core Technologies of Smart Medical System, ChongQing University of Posts and Telecommunications, ChongQing 400065, China
| | - Wei Xu
- Biomedical Engineering Department, Key Laboratory of Photoelectronic Information Sensing and Transmitting Technology, High School Innovation Team of Architecture and Core Technologies of Smart Medical System, ChongQing University of Posts and Telecommunications, ChongQing 400065, China
| | - Huiling Zhang
- Biomedical Engineering Department, Key Laboratory of Photoelectronic Information Sensing and Transmitting Technology, High School Innovation Team of Architecture and Core Technologies of Smart Medical System, ChongQing University of Posts and Telecommunications, ChongQing 400065, China
| | - Zhongyan Wang
- Biomedical Engineering Department, Key Laboratory of Photoelectronic Information Sensing and Transmitting Technology, High School Innovation Team of Architecture and Core Technologies of Smart Medical System, ChongQing University of Posts and Telecommunications, ChongQing 400065, China
| | - Haiyong Zhang
- Biomedical Engineering Department, Key Laboratory of Photoelectronic Information Sensing and Transmitting Technology, High School Innovation Team of Architecture and Core Technologies of Smart Medical System, ChongQing University of Posts and Telecommunications, ChongQing 400065, China
| | - Shuxing Zheng
- Biomedical Engineering Department, Key Laboratory of Photoelectronic Information Sensing and Transmitting Technology, High School Innovation Team of Architecture and Core Technologies of Smart Medical System, ChongQing University of Posts and Telecommunications, ChongQing 400065, China
| | - Yupan Shi
- Biomedical Engineering Department, Key Laboratory of Photoelectronic Information Sensing and Transmitting Technology, High School Innovation Team of Architecture and Core Technologies of Smart Medical System, ChongQing University of Posts and Telecommunications, ChongQing 400065, China
| | - Peng Xu
- Key Laboratory for NeuroInformation of Ministry of Education, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, China
| |
Collapse
|
41
|
Abstract
Pain modulates rhythmic neuronal activity recorded by Electroencephalography (EEG) in humans. Our laboratory previously showed that rat models of acute and neuropathic pain manifest increased power in primary somatosensory cortex (S1) recorded by electrocorticography (ECoG). In this study, we hypothesized that pain increases EEG power and corticocortical coherence in different rat models of pain, whereas treatments with clinically effective analgesics reverse these changes. Our results show increased cortical power over S1 and prefrontal cortex (PFC) in awake, freely behaving rat models of acute, inflammatory and neuropathic pain. Coherence between PFC and S1 is increased at a late, but not early, time point during the development of neuropathic pain. Electroencephalography power is not affected by ibuprofen in the acute pain model. However, pregabalin and mexiletine reverse the changes in power and S1-PFC coherence in the inflammatory and neuropathic pain models. These data suggest that quantitative EEG might be a valuable predictor of pain and analgesia in rodents.
Collapse
|
42
|
Simpraga S, Alvarez-Jimenez R, Mansvelder HD, van Gerven JMA, Groeneveld GJ, Poil SS, Linkenkaer-Hansen K. EEG machine learning for accurate detection of cholinergic intervention and Alzheimer's disease. Sci Rep 2017; 7:5775. [PMID: 28720796 PMCID: PMC5515842 DOI: 10.1038/s41598-017-06165-4] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Accepted: 06/09/2017] [Indexed: 12/21/2022] Open
Abstract
Monitoring effects of disease or therapeutic intervention on brain function is increasingly important for clinical trials, albeit hampered by inter-individual variability and subtle effects. Here, we apply complementary biomarker algorithms to electroencephalography (EEG) recordings to capture the brain’s multi-faceted signature of disease or pharmacological intervention and use machine learning to improve classification performance. Using data from healthy subjects receiving scopolamine we developed an index of the muscarinic acetylcholine receptor antagonist (mAChR) consisting of 14 EEG biomarkers. This mAChR index yielded higher classification performance than any single EEG biomarker with cross-validated accuracy, sensitivity, specificity and precision ranging from 88–92%. The mAChR index also discriminated healthy elderly from patients with Alzheimer’s disease (AD); however, an index optimized for AD pathophysiology provided a better classification. We conclude that integrating multiple EEG biomarkers can enhance the accuracy of identifying disease or drug interventions, which is essential for clinical trials.
Collapse
Affiliation(s)
- Sonja Simpraga
- Department of Integrative Neurophysiology, CNCR, Neuroscience Campus Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | | | - Huibert D Mansvelder
- Department of Integrative Neurophysiology, CNCR, Neuroscience Campus Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | | | - Geert Jan Groeneveld
- Centre for Human Drug Research, Leiden, The Netherlands.,Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
| | - Simon-Shlomo Poil
- Department of Integrative Neurophysiology, CNCR, Neuroscience Campus Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.,NBT Analytics BV, Amsterdam, The Netherlands
| | - Klaus Linkenkaer-Hansen
- Department of Integrative Neurophysiology, CNCR, Neuroscience Campus Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
| |
Collapse
|
43
|
Wagner NF, Chaves P, Wolff A. Discovering the Neural Nature of Moral Cognition? Empirical, Theoretical, and Practical Challenges in Bioethical Research with Electroencephalography (EEG). JOURNAL OF BIOETHICAL INQUIRY 2017; 14:299-313. [PMID: 28247203 DOI: 10.1007/s11673-017-9780-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Accepted: 11/27/2016] [Indexed: 06/06/2023]
Abstract
In this article we critically review the neural mechanisms of moral cognition that have recently been studied via electroencephalography (EEG). Such studies promise to shed new light on traditional moral questions by helping us to understand how effective moral cognition is embodied in the brain. It has been argued that conflicting normative ethical theories require different cognitive features and can, accordingly, in a broadly conceived naturalistic attempt, be associated with different brain processes that are rooted in different brain networks and regions. This potentially morally relevant brain activity has been empirically investigated through EEG-based studies on moral cognition. From neuroscientific evidence gathered in these studies, a variety of normative conclusions have been drawn and bioethical applications have been suggested. We discuss methodological and theoretical merits and demerits of the attempt to use EEG techniques in a morally significant way, point to legal challenges and policy implications, indicate the potential to reveal biomarkers of psychopathological conditions, and consider issues that might inform future bioethical work.
Collapse
Affiliation(s)
- Nils-Frederic Wagner
- Department of Philosophy, University of Duisburg-Essen, Lotharstr 65, 47057, Duisburg, Germany.
| | - Pedro Chaves
- Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal
| | - Annemarie Wolff
- Royal Ottawa Mental Health Centre, Mind, Brain Imaging and Neuroethics Research Unit, University of Ottawa Institute of Mental Health Research, 1145 Carling Avenue, Ottawa, ON, K1Z 7K4, Canada
| |
Collapse
|
44
|
Wilson FJ, Danjou P. Early Decision-Making in Drug Development: The Potential Role of Pharmaco-EEG and Pharmaco-Sleep. Neuropsychobiology 2016; 72:188-94. [PMID: 26900685 DOI: 10.1159/000382022] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2015] [Accepted: 03/30/2015] [Indexed: 11/19/2022]
Abstract
The pharmaceutical industry has been suffering from low clinical success rates of new drugs for some time with particularly high attrition in early clinical development, especially for drugs aimed at central targets. Both pharmaco-electroencephalography (EEG) and pharmaco-sleep, along with other biomarker techniques, have significant potential to assist with this problem by enabling early decisions to be made about the likelihood of a compound proving successful in the clinic. This paper discusses the role and points of application of biomarker techniques in early drug development. It proposes a framework for the use of pharmaco-EEG and pharmaco-sleep in drug development that (i) relies on the combination of preclinical data and an understanding of translatability to generate robust hypotheses for testing in early clinical studies and (ii) is backed up by a clear decision-making process. The areas that need further development before this framework can be put fully into practice are discussed, along with some possible routes by which this could be achieved through precompetitive co-operation within the industry.
Collapse
|
45
|
Anderer P. Advanced Analysis of Pharmaco-Sleep Data in Humans. Neuropsychobiology 2016; 72:178-87. [PMID: 26901054 DOI: 10.1159/000431097] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2015] [Accepted: 05/04/2015] [Indexed: 11/19/2022]
Abstract
Pharmaco-sleep studies in humans aim at the description of the effects of drugs, most frequently substances that act on the central nervous system, by means of quantitative analysis of biosignals recorded in subjects during sleep. Up to 2007, the only standard for the classification of sleep macrostructure that found worldwide acceptance were the rules published in 1968 by Rechtschaffen and Kales. In May 2007, the AASM Manual for the Scoring of Sleep and Associated Events was published by the American Academy of Sleep Medicine, and concerning the classification of sleep stages, these new rules are supposed to replace those developed by Rechtschaffen and Kales. As compared to the rather low interrater reliability of manual sleep scoring, semiautomated approaches may achieve a reliability close to 1 (Cohen's kappa 0.99 for 2 semiautomated scorings as compared to 0.76 for 2 manual scorings) without any decline in validity. Depending on the aim of the pharmaco-sleep study, additional analyses concerning sleep fragmentation, sleep microstructure, sleep depth, sleep processes and local aspects of sleep should be considered. For some of these additional features, rules for visual scoring have been established, while for others automatic analysis is obligatory. Generally, for reasons of cost-effectiveness but also reliability, automatic analysis is preferable to visual analysis. However, the validity of the automatic method applied has to be proven.
Collapse
|
46
|
Drinkenburg WHIM, Ruigt GSF, Ahnaou A. Pharmaco-EEG Studies in Animals: An Overview of Contemporary Translational Applications. Neuropsychobiology 2016; 72:151-64. [PMID: 26901596 DOI: 10.1159/000442210] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The contemporary value of animal pharmaco-electroencephalography (p-EEG)-based applications are strongly interlinked with progress in recording and neuroscience analysis methodology. While p-EEG in humans and animals has been shown to be closely related in terms of underlying neuronal substrates, both translational and back-translational approaches are being used to address extrapolation issues and optimize the translational validity of preclinical animal p-EEG paradigms and data. Present applications build further on animal p-EEG and pharmaco-sleep EEG findings, but also on stimulation protocols, more specifically pharmaco-event-related potentials. Pharmaceutical research into novel treatments for neurological and psychiatric diseases has employed an increasing number of pharmacological as well as transgenic models to assess the potential therapeutic involvement of different neurochemical systems and novel drug targets as well as underlying neuronal connectivity and synaptic function. Consequently, p-EEG studies, now also readily applied in modeled animals, continue to have an important role in drug discovery and development, with progressively more emphasis on its potential as a central readout for target engagement and as a (translational) functional marker of neuronal circuit processes underlying normal and pathological brain functioning. In a similar vein as was done for human p-EEG studies, the contribution of animal p-EEG studies can further benefit by adherence to guidelines for methodological standardization, which are presently under construction by the International Pharmaco-EEG Society (IPEG).
Collapse
|
47
|
Huang L, Yang XJ, Huang Y, Sun EY, Sun M. Ketamine Protects Gamma Oscillations by Inhibiting Hippocampal LTD. PLoS One 2016; 11:e0159192. [PMID: 27467732 PMCID: PMC4965035 DOI: 10.1371/journal.pone.0159192] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Accepted: 06/28/2016] [Indexed: 12/02/2022] Open
Abstract
NMDA receptors have been widely reported to be involved in the regulation of synaptic plasticity through effects on long-term potentiation (LTP) and long-term depression (LTD). LTP and LTD have been implicated in learning and memory processes. Besides synaptic plasticity, it is known that the phenomenon of gamma oscillations is critical in cognitive functions. Synaptic plasticity has been widely studied, however it is still not clear, to what degree synaptic plasticity regulates the oscillations of neuronal networks. Two NMDA receptor antagonists, ketamine and memantine, have been shown to regulate LTP and LTD, to promote cognitive functions, and have even been reported to bring therapeutic effects in major depression and Alzheimer’s disease respectively. These compounds allow us to investigate the putative interrelationship between network oscillations and synaptic plasticity and to learn more about the mechanisms of their therapeutic effects. In the present study, we have identified that ketamine and memantine could inhibit LTD, without impairing LTP in the CA1 region of mouse hippocampus, which may underlie the mechanism of these drugs’ therapeutic effects. Our results suggest that NMDA-induced LTD caused a marked loss in the gamma power, and pretreatment with 10 μM ketamine prevented the oscillatory loss via its inhibitory effect on LTD. Our study provides a new understanding of the role of NMDA receptors on hippocampal plasticity and oscillations.
Collapse
Affiliation(s)
- Lanting Huang
- Neurodegeneration Discovery Performance Unit, GSK, R&D Shanghai, Building 1, 917 Halei Road, Zhangjiang Hi-tech Park, Pudong, Shanghai, China
- Stem Cell Translational Research Center, Tongji Hospital, School of Medicine, Collaborative Innovation Center for Brain Science, Tongji University, Shanghai, China
| | - Xiu-Juan Yang
- Neurodegeneration Discovery Performance Unit, GSK, R&D Shanghai, Building 1, 917 Halei Road, Zhangjiang Hi-tech Park, Pudong, Shanghai, China
| | - Ying Huang
- Department of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Eve Y. Sun
- Stem Cell Translational Research Center, Tongji Hospital, School of Medicine, Collaborative Innovation Center for Brain Science, Tongji University, Shanghai, China
| | - Mu Sun
- Neurodegeneration Discovery Performance Unit, GSK, R&D Shanghai, Building 1, 917 Halei Road, Zhangjiang Hi-tech Park, Pudong, Shanghai, China
- * E-mail:
| |
Collapse
|
48
|
Kaiser AK, Doppelmayr M, Iglseder B. Electroencephalogram alpha asymmetry in geriatric depression : Valid or vanished? Z Gerontol Geriatr 2016; 51:200-205. [PMID: 27422260 DOI: 10.1007/s00391-016-1108-z] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Revised: 06/20/2016] [Accepted: 06/23/2016] [Indexed: 10/21/2022]
Abstract
BACKGROUND A correlation between asymmetry in electroencephalographs (EEG) and depression has been demonstrated in many studies. To the best of our knowledge there are no studies including oldest old geriatric patients. OBJECTIVE The objective of this study was to evaluate whether frontal and parietal alpha asymmetry can be used to differentiate between depressed and control patients in a cohort sample with a mean age of 80 years. MATERIAL AND METHODS Differences in the EEG were investigated in 39 right-handed female geriatric patients (mean age 80 years) with respect to frontal alpha asymmetry (FAA) and parietal alpha asymmetry (PAA) in depression (n = 14), depression combined with anxiety (n = 11) and normal controls (n = 14) as assessed with the hospital anxiety and depression scale (HADS). Band power was calculated for alpha 1 (6.9-8.9 Hz), alpha 2 (8.9-10.9 Hz) and alpha 3 bands (10.9-12.9 Hz). Furthermore, correlations between frontal and parietal alpha asymmetry and the geriatric depression scale (GDS), the HADS and the mini mental state examination (MMSE) were calculated. RESULTS A differentiation between the three groups was not possible with FAA and PAA. Significant correlations were found between PAA alpha 3 band and anxiety and depression. CONCLUSION The alpha asymmetry in EEG seemed to disappear with age. Correlations between PAA and anxiety and depression were found. The results are in line with the right (hemisphere) hemi-aging hypothesis.
Collapse
Affiliation(s)
- Andreas K Kaiser
- Department of Geriatric Medicine, Salzburger Landeskliniken Betriebs GesmbH, Christian-Doppler-Klinik, Paracelsus Medical University Salzburg, Ignaz-Harrer-Straße 79, 5020, Salzburg, Österreich. .,Department of Clinical Psychology, Salzburger Landeskliniken Betriebs GesmbH, Christian-Doppler-Klinik, Paracelsus Medical University Salzburg, Salzburg, Österreich.
| | - Michael Doppelmayr
- Department for Sport Sciences, University of Mainz, Mainz, Deutschland.,Center for Neurocognitive Research, University of Salzburg, Salzburg, Österreich
| | - Bernhard Iglseder
- Department of Geriatric Medicine, Salzburger Landeskliniken Betriebs GesmbH, Christian-Doppler-Klinik, Paracelsus Medical University Salzburg, Ignaz-Harrer-Straße 79, 5020, Salzburg, Österreich
| |
Collapse
|
49
|
Vardigan JD, Lange HS, Tye SJ, Fox SV, Smith SM, Uslaner JM. Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity. Psychopharmacology (Berl) 2016; 233:2441-50. [PMID: 27117142 DOI: 10.1007/s00213-016-4290-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2015] [Accepted: 04/03/2016] [Indexed: 12/13/2022]
Abstract
RATIONALE Much preclinical data, almost exclusively using rodent, supports the notion that phosphodiesterase 10A (PDE10A) inhibition may offer an alternative to the current standard of care in schizophrenia. However, concerns persist regarding the clinical translatability of these models for newer drug classes like PDE10A inhibitors. OBJECTIVES We therefore sought to characterize the clinical standard risperidone and the PDE10A inhibitor THPP-1 in nonhuman primate, both alone and when used as a combination therapy. METHODS THPP-1 and risperidone were tested in a novel rhesus model of stimulant-induced motor activity (SIMA) and in rhesus electroencephalography (EEG). RESULTS Consistent with rodent data, both THPP-1 and risperidone significantly attenuated the stimulant effects in SIMA when administered alone, though some differences were noted. Combination therapy with a low dose of risperidone produced significantly more robust effects. THPP-1 and risperidone also produced a marked reduction of wake cycle time and gamma frequency power in EEG. However, THPP-1 differed from risperidone by reducing spectral power of lower frequencies (delta). CONCLUSIONS SIMA results suggest that PDE10A inhibition produces antipsychotic-like effects in higher species, and that combination therapy with PDE10A inhibitors may produce more robust efficacy compared to monotherapies. EEG and qEEG results confirm that PDE10A inhibition does share some central signaling effects with clinically effective antipsychotics. The present combination therapy results may carry implications for the manner in which clinical testing of PDE10A inhibitors is conducted.
Collapse
Affiliation(s)
- Joshua D Vardigan
- Merck & Co., Inc., WP45-1114, 770 Sumneytown Pike, West Point, PA, 19486, USA
| | - Henry S Lange
- Merck & Co., Inc., WP45-1114, 770 Sumneytown Pike, West Point, PA, 19486, USA
| | - Spencer J Tye
- Merck & Co., Inc., WP45-1114, 770 Sumneytown Pike, West Point, PA, 19486, USA
| | - Steven V Fox
- Merck & Co., Inc., WP45-1114, 770 Sumneytown Pike, West Point, PA, 19486, USA
| | - Sean M Smith
- Merck & Co., Inc., WP45-1114, 770 Sumneytown Pike, West Point, PA, 19486, USA
| | - Jason M Uslaner
- Merck & Co., Inc., WP45-1114, 770 Sumneytown Pike, West Point, PA, 19486, USA.
| |
Collapse
|
50
|
Authier S, Delatte MS, Kallman MJ, Stevens J, Markgraf C. EEG in non-clinical drug safety assessments: Current and emerging considerations. J Pharmacol Toxicol Methods 2016; 81:274-85. [PMID: 26992360 DOI: 10.1016/j.vascn.2016.03.002] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2016] [Revised: 03/04/2016] [Accepted: 03/07/2016] [Indexed: 11/26/2022]
Abstract
Electroencephalogram (EEG) data in nonclinical species can play a critical role in the successful evaluation of a compound during drug development, particularly in the evaluation of seizure potential and for monitoring changes in sleep. Yet, while non-invasive electrocardiogram (ECG) monitoring is commonly included in preclinical safety studies, pre-dose or post-dose EEG assessments are not. Industry practices as they relate to preclinical seizure liability and sleep assessments are not well characterized and the extent of preclinical EEG testing varies between organizations. In the current paper, we discuss the various aspects of preclinical EEG to characterize drug-induced seizure risk and sleep disturbances, as well as describe the use of these data in a regulatory context. An overview of EEG technology-its correct application and its limitations, as well as best practices for setting up the animal models is presented. Sleep and seizure detection are discussed in detail. A regulatory perspective on the use of EEG data is provided and, tying together the previous topics is a discussion of the translational aspects of EEG.
Collapse
Affiliation(s)
- Simon Authier
- CiToxLAB North America, 445 Armand Frappier, Laval, QC H7V 4B3, Canada.
| | - Marcus S Delatte
- Division of Anesthesia, Analgesia and Addiction Products (DAAAP), CDER, U.S. Food & Drug Administration, Silver Spring, MD, USA
| | | | - Joanne Stevens
- Department of Pharmacology, Merck Research Laboratories, West Point, PA 19486, USA
| | - Carrie Markgraf
- Safety Assessment, Merck Research Laboratories, Kenilworth, NJ 07033, USA
| |
Collapse
|